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A major barrier for using non-viral vectors for gene therapy is the short duration of 
transgene expression in postmitotic tissues. Previous studies showed transgene 
expression from conventional plasmid fell to sub-therapeutic levels shortly after 
delivery even though the vector DNA was retained, suggesting transcription was 
silenced in vivo. Emerging evidence indicates that the bacterial backbone sequence of 
the plasmid is responsible for the transcriptional repression and this process is 
independent of CpG methylation. Dumbbell-shaped DNA vectors (dbs) consisting 
solely of essential elements for transgene expression have been developed to 
circumvent these drawbacks. Previous studies showed db induced higher levels of 
transgene expression both in vitro and in vivo. Increasing interest has been focused on 
small non-coding RNAs since their discovery. Artificially designed short hairpin 
RNAs (shRNAs) hold great promise for therapeutic purposes, and endogenous 
microRNAs (miRNAs) have also been shown to be aberrantly expressed in many 
pathological processes. Delivery of small RNA with therapeutic benefits may provide 
treatments for diseases that are currently considered untreatable. Sensitive and cost-
efficient small-RNA detection technology is needed for the study of small-RNAs. 
We developed a new method for the detection of small RNAs. This TaqMan RT-
PCR-based method uses a stem-loop reverse transcription primer to capture the 3’ end 
of target RNA, and cDNA is amplified using a specific forward primer and a 
universal reverse primer as well as a universal TaqMan probe. Such a design allows 
us to use a single TaqMan probe for the detection of multiple targets and therefore 
significantly reduces the costs. By comparing this novel method with the state-of-the-
art technology we show that both protocols are equally sensitive and specific. We 
xi 
 
have demonstrated the applicability of this new method for the detection of 
endogenous as well as artificial eukaryotic small RNAs. We further revealed and 
discussed previously unknown limitations of TaqMan probe-based small RNA 
detection. 
We investigated novel molecular features of non-coding and coding RNA-expressing 
dumbbell vectors that either reduced vector size thereby accelerating delivery and 
gene expression, or alternatively enhanced vector activity. Small hairpin (sh)RNA or 
micro(mi)RNA expressing vectors were reduced in size down to 130 base pairs by 
transcribing the RNA hairpin structure around the dumbbell loop using a minimal H1 
promoter with integrated inverse transcriptional terminator. Notably, these dumbbell 
vectors are the smallest expression vectors ever reported. Our comparison of shRNA-
expressing dumbbells with plasmids revealed strongly accelerated kinetics of cellular 
delivery, nuclear delivery (up to 74-fold), transcription (up to 12-fold), and target 
gene knockdown triggered by the dumbbell vectors in human tissue culture cells. 
Compared with conventional dumbbells, minimised dumbbells exhibited up to 4-fold 
accelerated kinetics of transcription and enhanced target gene knockdown. A miRNA 
stem or SV40 enhancer-derived elements further improved the knockdown activity. 
Finally, implementation of the SV40 enhancer and a spliceable intron enhanced 
dumbbell-driven gene expression up to 56-fold (160-fold compared with a standard 
plasmid) depending on the tested cell line. Long-term kinetics of transgene expression 
from a GFP db and the corresponding plasmid were also monitored in Jurkat cells as 
well as in human PBMCs indicating that plasmid- but not dumbbell-driven gene 
expression is silenced in human primary cells. The advanced molecular design may 
facilitate pre-clinical and clinical applications of dumbbell vectors in the near future. 
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1.1 Overview of gene therapy 
Gene therapy is generally defined as the approach to prevent or reverse a pathological 
process by introducing specific nucleic acids into the target cells (Kay 2011). The 
basic idea of gene therapy was conceived quite a long time ago, but it was not until 
the establishment of the recombinant DNA technology that it received serious 
attention. Initially it was perceived that this new technology would be revolutionary 
as it held the promise to cure any disease as long as we understood the genetic or 
molecular basis of aetiology. However the enthusiasm was soon tempered because 
most of the clinical trials failed to show efficacy (Scollay 2001). Moreover, the safety 
of the new molecular medicine was also a big concern since the first vehicles used for 
gene therapy were recombinant viral vectors. With the recent research progress, we 
have got a more thorough understanding of the molecular biology of exogenous gene 
delivery and expression, some technical barriers have been overcome and examples of 
treating certain diseases using gene therapy have already been reported. 
Goals for gene therapy include gene addition, gene correction and gene knockdown, 
and sometimes these routes are used in combination. Gene addition is used to provide 
therapeutic benefit when certain protein is dysfunctional, possibly due to mutation. 
Gene correction, or alternation, is the most difficult to realize due to technical 
requirements. However, with recent progress in genome editing technologies, such as 
zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) 
and CRISPR/cas system, many barriers have been overcome now. Gene knockdown 
has become the most popular strategy for gene therapy owing to the elucidation of 
miRNA and siRNA biogenesis pathways and the phenomenon of RNA interference in 
the 1990s and thereafter. Currently, more than 20 RNAi-based drugs are investigated 
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in clinical trials and this approach is the most likely to provide clinical benefits in the 
near future.  
4 
 
1.2 Technical barriers to successful gene therapy 
Many types of vectors have been developed for gene therapies. In the last decade, 
gene transfer into cells and in vivo significantly improved, mainly owing to the 
development of novel vector technologies. Vector systems have been refined, the 
production protocols of many vectors have been simplified, transduction rates have 
been increased, and safety profiles have been improved. However, there are still 
major barriers to overcome before gene therapy can be widely used in clinical settings. 
In order to achieve therapeutic levels of transgene expression, the vector encoding the 
transgene must be taken up efficiently by the target tissue. Gene therapy vectors can 
either be administered to the body either locally, for example by tissue injection, or by 
systemic means, such as intravenous infusion (Kay 2011). Once administered, the 
biodistribution of the vector should be carefully examined. The biodistribution can be 
affected by many factors, including interactions between the vector ligand and the 
host cell receptor, the endothelial barriers of a particular organ. Toxicity of a vector is 
significantly affected by the degree of inadvertent vector uptake by other non-target 
tissues. Non-viral vectors tend to be degraded very fast by nucleases in physiological 
fluids and the extracellular matrix. It has been estimated that the half-life of 
intravenously delivered plasmid DNA is only ten minutes in mice (Kawabata, 
Takakura et al. 1995). Therefore it is very important to use certain carriers to provide 
protection and improve the circulation time. Some commonly used carriers include 
the zwitterionic lipids, polyplexes and lipoplexes or liposomes (Koltover, Salditt et al. 
1998, McManus, Radler et al. 2004, Pack, Hoffman et al. 2005). When vectors are 
delivered using helper carriers, vector unpacking and release of the nucleic acid 
represents another barrier for transgene expression. However, to which extent the 
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dissociation affects gene delivery is not very clear. For lipoplexes, it is assumed that 
the fusion of cationic lipid with endosomal membrane can facilitate endosomal escape 
and DNA release (Wasungu and Hoekstra 2006). Polyplexes, on the other hand, 
remain intact before they are translocated into the nucleus where they undergo 
dissociation (Breunig, Lungwitz et al. 2005). Transgene expression from lipoplex-
delivered plasmids is about tenfold higher than that from polyplex-delivered 
counterparts, which might be caused by inefficient polyplex dissociation in the 
nucleus (Cohen, van der Aa et al. 2009).  
Although a great deal of effort has been spent, it is still challenging to achieve cell-
type-specific delivery, and this is the case for both non-viral and viral vector 
platforms. Non-viral vectors can be conjugated with specific ligands, and viral vector 
capsids or envelop protein can be genetically engineered. However, up to now these 
strategies have not shown success in clinical applications. The modifications usually 
make the vector too large or too unstable. A viral vector, once it enters the host cell, 
can efficiently progress from the cytoplasm to the nucleus through the viral infection 
pathway. Non-viral vectors, on the other hand, have to overcome two additional 
barriers: escaping from endosomal degradation and crossing of the nuclear membrane. 
Inefficient cellular internalization, escape from the endosome and nuclear transport 
can all result in unsatisfactory transgene expression. Particularly, both deterministic 
and stochastic kinetic models of synthetic gene delivery have indicated that nuclear 
uptake is the rate-limiting step (Varga, Tedford et al. 2005, Dinh, Pangarkar et al. 
2007). A microinjection experiment has shown that when plasmid DNA encoding the 
thymidine kinase was injected into the nuclei, 50-100% of the nuclei expressed the 
gene product, whereas when it was injected into the cytoplasm, no protein activity 
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was detected in more than 1,000 cells (Capecchi 1980). The nuclear barrier can 
further be highlighted by the observation that for in vitro transfection, it is usually 
easier to transfect cells that divide rapidly since they frequently undergo breakdown 
of the nuclear envelopes (Miller and Dean 2009). 
Vector genome persistence is also an important parameter that affects the therapeutic 
performance. Some vectors are designed to persist episomally after delivery. It is 
assumed that the expression from these vectors is transient, because most of the vector 
DNA will be lost during cell division and by vector degradation. However, long-term 
persistence has been observed in rodents and other larger animals, when episomal 
vectors were delivered into relatively quiescent tissues, such as heart, liver, or muscle 
(Kennedy, Rettinger et al. 1995, Thomas, Ehrhardt et al. 2003). Vectors that integrate 
into the host genome can trigger stable long-term stable expression, and are therefore 
more suitable to induce expression in actively dividing cells, such as the 
haematopoietic stem cells. However, host integration is usually associated with 
insertional mutagenesis that can cause severe adverse effects. Both integrated and 
episomal vector genomes can be efficiently silenced in host cells by epigenetic 
modifications. Several studies with non-viral vectors showed that silencing of plasmid 
DNA happened within a short period after delivery, and transgene expression was 
turned off even though the vector DNA was not lost (Chen, He et al. 2004). Silencing 
of the vector genomes is reflected by chromatin-linked transcriptional blockage 
(Gracey Maniar, Maniar et al. 2013). The duration of transgene expression is crucial 
for the treatment of a disease. For genetic diseases, lifelong expression of the intact 
transgene is often required. Although this can be achieved by repeated transient 
administration of the vector, a better understanding of the in vivo silencing process 
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and the development of strategies to escape silencing would significantly improve the 
therapy.  
Therapeutic outcome is also affected by the expression efficiency. Expression of the 
transgene is affected by the promoters used. For coding-gene expression, in order to 
achieve high levels of expression in various types of mammalian cells, viral enhancers 
and promoters derived from cytomegalovirus (CMV), simian virus 40 (SV40) and 
respiratory syncytial virus (RSV) are frequently used. However, expression from 
these vectors is always transient (Gill, Pringle et al. 2009). Constitutive mammalian 
promoters such as the human ubiquitin C (UBC) and the eukaryotic translation 
elongation factor 1 alpha (EEF1A) promoters, on the other hand, can provide more 
persistent expression (Gill, Smyth et al. 2001). Tissue-specific promoters are also 
used when expression need to be restricted to specific types of cells, for example, the 
alpha-fetoprotein (AFP) enhancer-albumin (ALB) promoter can be used when the liver 
is the targeted organ (Wooddell, Reppen et al. 2008). For small non-coding RNAs, 
usually RNA polymerase III promoters including U6 and H1 are used for expression. 
In addition to transcription, expression efficiency can also be affected by subsequent 
RNA processing and nuclear export of the transcribed RNA. Export and translation of 
the mRNA can be improved by removal of the aberrant AUGs and insertion of an 
intron (Engels, Cam et al. 2003). Addition of the woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) has also been reported to enhance 
transgene expression by either polyadenylation or translation modification 
(Schambach, Wodrich et al. 2000). Processing and nuclear export of delivered small 




Host immune response activation is also a major barrier that diminishes the 
therapeutic benefits from gene therapy. Both the transgene product and the delivery 
vector particles can induce host immune responses. An immune response against the 
vector can limit its efficacy or re-administration, whereas the immune response 
against transgene product can neutralize the protein that generates therapeutic benefits. 
Moreover, innate responses can sometimes cause severe toxicity. Viral infections are 
naturally subject to humoral immune response; therefore it is not surprising that many 
viral vectors activate the human immune system. This limits the usefulness of viral 
vector-based therapy especially when re-administration is necessary. To circumvent 
the problems associated with immune activation, harmless viral serotypes that 
infrequently infect humans are currently being investigated, such as some adenoviral 
serotypes (Stone and Lieber 2006). Humoral responses can also be activated by non-
viral vectors. Various components of the non-viral delivery system, for example, 
proteins, carbohydrates or even lipids, can serve as antigens. Immunity can also be 
directed against the transgene product, especially when the vector is taken up by off-
target tissues. Since cell-type-specific delivery is technically challenging, currently 
the most effective way is to use cell-type specific promoters to limit the expression to 
the intended cells. Recently another strategy that takes advantage of cell-type-specific 
differential miRNA expression has also been used successfully to avoid unintended 
transgene expression in antigen-presenting cells (APCs) (Brown, Venneri et al. 2006, 
Brown, Gentner et al. 2007). Because the human immune system is extremely 
complex and our understanding about it is very limited, it is impossible to predict both 
innate and antigen-dependent immune responses against a certain vector. In most 
situations human immune responses also cannot be recapitulated in animal models. 
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Therefore, all vector-based gene transfer data derived from non-human species may 




1.3 Non-viral vectors for gene therapy 
Both viral and non-viral vectors are tested in clinical trials for gene therapy. Though 
~70% of the trials carried out so far chose viral vectors as delivery vehicles, there are 
some limitations associated with these vectors, including the integration-related risk 
of carcinogenesis, immunogenicity, limited DNA packaging capacity and high 
production costs (Yin, Kanasty et al. 2014). Non-viral vectors, on the other hand, are 
generally considered much safer: they tend to have lower immunogenicity than their 
viral counterparts, and they remain episomal in nature (Mintzer and Simanek 2009). 
Moreover, production of non-viral vectors is more straightforward and they also have 
the potential to deliver larger genetic material (Pack, Hoffman et al. 2005). However, 
at the current stage, non-viral vectors are limited by their low delivery efficiency and 
the short duration of transgene expression. While viruses have evolved sophisticated 
strategies to efficiently deliver their genomes into mammalian cells, several barriers 
must be overcome before the non-viral vectors transport their payloads, including 
serum endonucleases degradation, immune detection, extravasation, diffusion through 
the extracellular matrix network, cellular uptake, endosomal escape, nuclear import, 
nuclear retention and stability, transcriptional activity, RNA processing and export, 
and efficient translation or gene silencing in the cytoplasm. 
Non-viral vectors can be divided into two basic components, the nucleic acid 
molecule and the delivery constituent with helper function. The most commonly used 
nucleic acid molecule is DNA, either as plasmids or as alternative vectors, such as 
minicircles and dumbbell-shaped vectors (dbs). With recent advances in nucleic acid 
chemistry, RNA molecules have also been used in vivo, including mRNAs, miRNAs 
and siRNAs (Yin, Kanasty et al. 2014). As for the delivery constituent, developments 
in material sciences and the rapid progress of nanotechnologies have provided more 
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efficient options for delivery, for example new polymers, lipids, and nanosized 
material (Putnam 2006, Semple, Akinc et al. 2010, Monopoli, Aberg et al. 2012). A 






Adeno-associated viral (AAV) vectors 
Non-viral vectors 










Table 1. Summary of vectors used in gene therapy. 
 
1.3.1 In vivo delivery of non-viral vectors 
Although in vivo delivery of non-viral vectors is inefficient, some progress has been 
made over the last decade. Non-viral vectors can be delivered via various routes, 
including intravenous infusion or oral ingestion (Dang and Leong 2006). 
Hydrodynamic transfection has been reported to be an efficient method for liver 
delivery in mice. This technology consists of a high-pressure infusion of naked DNA 
into the tail vein of a mouse. Hydrodynamic transfection can successfully transfect up 
to 40% of hepatocytes, however the underlying mechanism of this method is not well 
understood (Liu and Knapp 2001). Hydrodynamic transfection has also been studied 
for the delivery into hepatic vasculature in pigs and humans. Though this technology 
is safe to use in the clinical setting, its efficiency still need further improvement in 
order to achieve a clinical benefit (Khorsandi, Bachellier et al. 2008). A similar 
strategy can be used for muscle delivery, such as skeletal muscle groups or cardiac 
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muscles (Wolff and Budker 2005). Other technologies for delivery include 
electroporation, nucleofection, jet injection, ballistic delivery using the gene gun, and 
ultrasound-guided DNA uptake (Andre and Mir 2004). The value of these 
technologies for clinical therapies remains to be evaluated. 
1.3.2 Integrating non-viral vectors 
Although non-viral vectors mainly exist episomally in cells, there are several 
strategies to achieve transgene integration in target cells. One of the strategies takes 
advantage of DNA transposons. In this strategy, a therapeutic expression cassette 
flanked by specific transposon DNA sequences and a transposase expression construct 
are co-introduced into the target cells, which induces stable integration of the 
transgene into the host cell chromosome (Ivics and Izsvak 2010). Sleeping Beauty, an 
ancient transposon isolated from salmon, was the first to be used in mammals for gene 
therapy (Izsvak and Ivics 2004). Since then many other DNA transposons have been 
examined in preclinical gene transfer studies, including piggyBac, Harbinger-Dr3. 
The integration of a DNA transposon is determined by the specific nucleotide 
sequences they recognize. Another strategy for non-viral vector integration includes 
the use of bacteriophage recombinases. Transient expression of the recombinase can 
lead to integration of the transgene into pseudo-sites resembling the original 
prokaryotic sequence that the recombinase recognizes (Calos 2006, Chalberg, 
Portlock et al. 2006). Compared to DNA transposons, recombinase-mediated 
integration is in general more site-specific. However, they can sometimes lead to 
chromosomal translocations, which is not observed with DNA transposons (Ehrhardt, 
Xu et al. 2005). In summary, the safety of both DNA transposons and bacteriophage 





Minicircles are alternative non-viral vectors derived from conventional plasmid DNA 
by site-specific recombination in bacteria. They are supercoiled, double-stranded 
DNA vectors that contain only the minimal expression cassettes, but lack bacterial 
backbone sequences, antibiotic resistance genes and origins of replication. Compared 
with plasmids, minicircles have been shown to provide much higher transgene 
expression both in vitro and in vivo (Mayrhofer, Schleef et al. 2009). 
A plasmid vector consists of bacterial backbone and a transcription unit. Whereas the 
transcription unit encodes the gene of therapeutic interest, the bacterial backbone 
carries elements such as an antibiotic resistance gene, an origin of replication 
sequence, and potentially cryptic expression signals (Jechlinger 2006). The bacterial 
backbone is required for plasmid production in bacteria but can cause serious 
biological safety problems when introduced into mammals or humans for gene 
therapy. It is also recommended by regulatory agencies that antibiotic resistance 
markers should be avoided for therapeutic purposes (Site 2001). In addition to the 
potential risk of dissemination of antibiotic resistance genes, leaky expression of 
bacterial genes represents another safety concern. It has been shown that when 
plasmid DNA without any eukaryotic elements was injected intramuscularly into 
rabbits, it led to the expression of bacterial sequences and induced an unintended 
immune response (Pang 1994). Cryptic expression of the antibiotic gene triggered by 
upstream eukaryotic expression signals has also been reported (Hartikka, Sawdey et 
al. 1996). The unmethylated CpG motif in bacterial DNA can also activate the innate 
immune system by binding to the Toll-like receptor 9 (TLR9) (Klinman 2004). 
Because the bacterial backbone does not have any therapeutic effects and is associated 
with biosafety concerns, it is obvious that they should be eliminated for non-viral 
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gene therapy. Alternative vectors that contain no bacterial sequences are therefore 
developed, most notably minicircles and dumbbell-shaped vectors (dbs). 
To produce minicircles, researchers induce site-specific recombination in bacteria. 
The transgene expression cassette is usually flanked by recognition sites of 
recombinase and in vivo expression of the corresponding recombinase results in the 
excision of the interjacent DNA sequences. The parental plasmid is divided into two 
supercoiled molecules after the recombination process, namely the minicircle and the 
miniplasmid, the latter of which carries the undesired bacterial backbone sequences. 
Several different recombinases have been explored for minicircle production, 
including the λ integarase family, the Cre recombinase, the FLP recombinase, and the 
serine recombinase family (Phi31 and ParA resolvase) (Mayrhofer, Schleef et al. 
2009). Stringent control of recombinases repression and expression is very important 
for efficient recombination. The recombinase needs to be silenced in the initial culture 
to avoid premature recombination, which will displace the parental plasmid by the 
miniplasmid. On the other hand, a high expression level of the recombinase is needed 
at the last stage in the culture to achieve high recombination rates. Temperature-
sensitive lambda cI857/pR promoter and PBAD/araC arabinose expression systems are 
commonly used to control the expression of the recombinase (Chen, He et al. 2003, 
Nehlsen, Broll et al. 2006). 
Minicircles need to be purified after the recombination step from the producing 
bacteria and by-products including the miniplasmid and residual parental plasmid 
need to be eliminated. The most widely used method is to first linearize the 
miniplasmid and residual parental plasmid by restriction digestion, and then separate 
the minicircle from the by-products via ultracentrifugation in cesium chloride. 
However, this method gives relatively low yields of minicircle DNA and is labour-
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intensive. Chen et al. have developed a modified method that degrades the by-
products in the bacteria avoiding the digestion and ultracentrifugation steps (Chen, He 
et al. 2005, Kay, He et al. 2010). This new method greatly simplifies the production 
procedure of minicircles, but it has been reported that the clearance of by-products is 
not 100%, some miniplasmids and parental plasmids are still co-purified with the 
minicircles (Chen, He et al. 2005). 
Minicircles have been shown to lead to higher transgene expression levels both in 
vitro and in vivo. Darquet et al. first compared the performance of minicircle vectors 
and parental plasmids in cell culture experiments (Darquet, Cameron et al. 1997). 
Their data suggested that when equal molarities of constructs were transfected, the 
minicircle vector yielded three to ten times higher expression levels than the parental 
plasmid, depending on the cell lines used. As expected, a more significant increase of 
transgene expression was observed when the same total amounts of minicircle DNA 
and parental plasmid (weight-to-weight) were transfected, because equal amounts of 
minicircle DNA relate to a higher number of gene expression cassettes (Darquet, 
Rangara et al. 1999, Bigger, Tolmachov et al. 2001). The effect of minicircle DNA 
application in vivo was even more profound than in vitro. In the first in vivo 
experiment conducted by Scherman et al., injection of minicircle DNA into mouse 
cranial tibial muscle or human head and neck carcinoma cells gave 13-50 times more 
transgene expression, based upon a weight-to-weight comparison (Darquet, Rangara 
et al. 1999). More impressive results were reported by the group of Mark Kay. In their 
study, they compared the performance of equimolar amounts of 1) purified linear 
expression cassettes, 2) a mixture of linearized expression cassette together with the 
linearized bacterial backbone, 3) conventional plasmid, and 4) minicircle DNA 
generated from the plasmid. All constructs expressed the human 1-antitrypsin 
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(hAAT) gene under the control of the Rous sarcoma virus (RSV) promoter. DNA 
constructs were introduced into mice by hydrodynamic injection, and transgene 
expression was evaluated by measuring the serum concentrations of hAAT. Their data 
showed that transgene expression triggered by the minicircles was significantly higher 
than that from all the other three groups, and serum concentrations of the mice which 
had received the minicircle DNA were 200- to 560-fold higher than those of mice that 
received parental plasmid (Chen, He et al. 2003). Efficient silencing of plasmid DNA 
but not the minicircle in vivo was observed in this study. This phenomenon was 
further confirmed by another group led by Huang using an interferon (IFN)- 
encoding minicircle (Wu, Xiao et al. 2006).  
Transgene silencing from parental plasmid was first proposed to be a consequence of 
CpG motif-triggered inflammatory responses. It was presumed that this unwanted side 
effect associated with the bacterial backbone might lead to necrosis- or apoptosis-
mediated cell death of transduced cells (Tan, Li et al. 1999). However, recent 
progresses suggest that immune response may not be the main mechanism for 
transgene silencing. In the study by Chen et al. mentioned above, it was already 
demonstrated that the covalent linkage of bacterial backbone to the transgene 
expression cassette was indispensable for the silencing process (Chen, He et al. 2003). 
They were also able to show that all DNA constructs persisted in the cells for an equal 
time, demonstrating that silencing was not caused by selective DNA loss. A further 
investigation of molecular mechanisms of transcriptional silencing suggested 
silencing was probably associated with chromatin modifications. A high ratio of 
H3K9me to H3K4me was detected in the bacterial sequences, indicating that they 
were recognized by mammalian cells and packed rapidly into inactive 
heterochromatic form. The inactive chromatin pattern was hypothesized to spread into 
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the transgene coding eukaryotic elements and induce the silencing, as a gradual 
increase of H3K9me to H3K4me ratio was detected (Suzuki, Kasai et al. 2006). 
Recently it was proposed that the extragenic spacer length between the 5’ and 3’ ends 
of the transgene expression cassette is important for the silencing process, as silencing 
was only observed when the length of the spacer was above 1 Kb, regardless of the 
origin of the sequences (Lu, Zhang et al. 2012). 
Studies of minicircle vectors have provided us invaluable information for the design 
and development of alternative non-viral vectors for gene therapy. Evidence suggests 
that the bacterial backbone is associated with the silencing of transgene expression, 
therefore accounting for the unsatisfactory results using conventional plasmids in 
model animals and clinical trials. Novel vectors like minicircle vectors, and dumbbell-




1.4 Dumbbell-shaped vectors 
Dumbbell-shaped DNA vectors (dbs) are novel non-viral expression constructs that 
have been successfully applied in several areas, particularly for immunization against 
infectious diseases and for tumour therapies (Schmidt, Volz et al. 2008). Similar to 
minicircles, dbs only consist of a minimalistic genetic content, but lack bacterial 
sequences that are irrelevant to therapeutic applications. The structure of dbs is linear, 
covalently closed with single-stranded loops at both ends. Such a design renders the 
dbs resistant to exonuclease degradation. Dbs are characterized by their small size and 
flexibility. The loops that used to close the vector can be covalently attached to 
various molecules, for example peptides, or antibodies, depending on the purpose of 
the application. In one previous study, linkage of a db vector with the TH-1 peptide 
showed increased potency for immune response induction (Endmann, Baden et al. 
2010). Although most dbs are developed for gene transfer purposes, these vectors 
have also been successfully used as immunomodulators or decoy molecules. One 
example is the dSLIM
TM
 molecule (Double-Stem Loop ImmunoModulator) 
developed by Mologen. dSLIMs are non-coding, DNA-based molecules that contain 
non-methylated CpG motifs. They induce a defined immunomodulatory response 
such as activation of immune cells because of their unique structure. dSLIM
TM
s have 
been combined with gene-coding dbs (for example, MIDGE
TM
, Mologen) or 
chemotherapy for cancer treatment, and this strategy is currently being tested in 
clinical trials (NCT02077868, NCT02200081, NCT01265368 ClinicalTrials.gov). 
1.4.1 Structure of dumbbell vectors 
Protein-coding db vectors are usually derived from parental plasmids and contain only 
the minimalistic expression cassette. Smaller dbs, such as non-coding 
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immunomodulators, DNA decoys, and small-RNA expressing dbs, on the other hand, 
can be synthesized by in vitro annealing and ligation of oligodeoxyribonucleotides or 
PCR-based methods. Db vectors show linear covalently closed topology with single-
stranded loops on both ends. Schematic structures of coding and non-coding dbs are 
shown in Figure 1. 
 
Figure 1. Schematic drawings of coding (MIDGE
TM
) and non-coding (dSLIM
TM
) 
db molecules. ODN, oligodeoxyribonucleotides. 
Adapted from Schmidt et al. 2008. 
 
Coding dbs only consist of genetic content essential for transgene expression, 
including promoter, CDS and polyadenylation signal. A chimeric intron was included 
in some dbs to enhance the expression (Schakowski, Gorschluter et al. 2001). Such a 
design leads to the characteristic small size of these vectors. It is also possible to 
express multiple genes, or protein-coding genes together with non-coding RNAs, in a 




1.4.2 Production of dumbbell vectors 
Various production strategies have been developed over time for the production of 
different dbs. The most commonly used method for db production is based on the 
enzymatic ligation assisted by nucleases (ELAN) strategy, as shown in Figure 2.  
 
Figure 2. Illustration of the production process for db vectors using ELAN loop-
ligation method.  
 
In this strategy, a parental plasmid containing the transgene expression cassette is first 
digested with two restriction endonucleases that recognize sites flanking the 
transcription unit. After the digestion step, oligonucleotides (ODNs) suitable to ligate 
to the digestion-generated cohesive DNA ends and to form the terminal loop 
structures are added. The ELAN strategy suppresses the formation of misligated 
21 
 
products by restriction endonucleases which cleave off-pathway products during the 
ligation step. Properly ligated dbs are subsequently obtained during the T7 DNA 
polymerase treatment, which exhibits strong 3’-5’ exonuclease activity (Holmgren, 
Kallis et al. 1981, Engler and Richardson 1983). The bacterial backbone and 
misligated by-products are degraded by the exonuclease treatment. Remaining dbs are 
further purified by standard DNA purification methods, such as phenol extraction, 
column-based purification, or HPLC. The overall workflow for this method can be 
performed in one single tube with sequential addition of enzymes, and only one final 
purification step is necessary. The manufacturing process can be easily adapted to 
cGMP standards and used in clinical settings.  
Another strategy for efficient biochemical synthesis of dbs around 100 bp was 
reported by Kuhn and co-workers (Kuhn, Frank-Kamenetskii et al. 2001). They 
started with a pair of short DNA hairpins with long single-stranded tails of arbitrary 
sequence. Dbs were produced by enzymatic ligation, and then unligated or 
monoligated by-products were multiply biotinylated via nick-translation or primer-
extension or both. These by-products could therefore readily be removed from the dbs 
by a biomagnetic separation procedure. A schematic illustration of this strategy is 




Figure 3. Outline of synthetic strategy for preparation of a DNA dumbbell.  
Two oligonucleotides (ODN1 and ODN2) are annealed and ligated, yielding closed, 
double-ligated dumbbell as the major product. By-products, such as unligated and 
monoligated dumbbells, containing nicks or gaps are subsequently labelled with 
several biotin groups via nick-translation or primer-extension (or both) in the presence 
of biotinylated dCTP. After incubation with streptavidin-coated magnetic beads, the 
labelled by-products are removed from unlabelled, closed dumbbell by affinity 
capture on a magnetic separator. 
 
Taki et al. have introduced another PCR-based nicking enzyme-dependent method for 
db production (Taki, Kato et al. 2004). In their strategy, the transcription unit is 
amplified by PCR with primers that include specific nicking enzyme restriction sites. 
The PCR product is then digested by the nicking enzymes, which only cut one strand 
of the double-stranded DNA. The uncut strand is designed in a way that after the 
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digestion it folds back and forms the loop structure. The overall conversion yields of 
this nicking enzyme-based method were reported to be >90%, probably due to the 
intramolecular ligation nature of this method, which should be more efficient than 
intermolecular ligation in the loop-ligation based method. General scheme for this 
PCR-based strategy is summarized in Figure 4. 
 
Figure 4. General scheme for the direct and efficient synthesis of dumbbell-
shaped DNA by in vitro PCR.  
Nb.Bpu10I is a site- and strand-specific nicking endonuclease artificially engineered 
from Bpu10I that cleaves only one strand of the DNA within its recognition sequence 






1.4.3 Advantages of dumbbell vectors 
There are a variety of advantages to use db vectors for therapeutic applications. 
Compared with plasmids, dbs can be designed free from CpG motifs to avoid 
undesired inflammatory reactions and auto-immunity in animals or humans 
(Tousignant, Zhao et al. 2003, Hodges, Taylor et al. 2004). Similar to minicircles, db 
vectors are free from sequences that are not necessary for transgene expression. These 
sequences are required for plasmid multiplication in bacteria and are associated with 
safety concerns. Furthermore, no immune response against basic vector constituent is 
induced by db vectors, nor do they evoke any allergic anti-vector-reactions in 
recipients. The unique topology of db vectors makes them easily accessible to linkage 
chemistry, independent of the chemical nature of the attached molecules. New 
features can be added to db vectors by linking specific molecules, such as proteins, 
peptides, lipids, biotin. Various possible modifications to db vectors are shown in 




Figure 5. Schematic drawing of db vectors (left column) linked with various 
molecules (middle column) for defined purposes (right column).  
Adapted from Schmidt et al. 2008. 
 
Compared with plasmids, comparable or higher expression levels have been reported 
for db vectors (Schakowski, Gorschluter et al. 2001, Schakowski, Gorschluter et al. 
2007). Finally, the biotechnological production of db vectors is straightforward and 
cheap. More importantly, the production procedure can easily be adapted to cGMP 
standards, which facilitates their use in clinical settings. In summary, db vectors are 
novel alternative gene transfer vehicles that are non-supercoiled, non-replicating and 
non-integrating, though a very low integration rate cannot be excluded. The 
impressive safety profile makes them superior to plasmids and viral vectors. 
1.4.4 Applications of dumbbell vectors 
Schakowski and co-workers first compared the transfection and expression efficiency 
of dbs and parental plasmids using colon carcinoma cells (Schakowski, Gorschluter et 
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al. 2001). They used various transfection technologies, including cationic lipids, 
cationic polymers and electroporation, to deliver equal amounts of DNA (weight to 
weight) into colon cancer cell lines SW480 and HT-29. Transfection efficiency was 
measured both qualitatively and quantitatively using the GFP reporter gene and was 
found to be comparable for both vectors. Using another reporter gene, human 
interleukin-2, they showed that expression levels from db vectors were approximately 
two- to four-fold higher than those from the plasmid counterparts. Then the same 
group continued to investigate the performance of db vectors in vivo (Schakowski, 
Gorschluter et al. 2007). They used hydrodynamics-based, systemic transfection to 
introduce both db and corresponding plasmid encoding luciferase reporter gene into 
BALB/c mice. Transfection efficiencies, as measured by luciferase activity, were 
found to be significantly higher in liver, lung, kidney, and heart. For the in vivo 
comparison, equal molarities of db and plasmid were used. They then measured the 
copy number of delivered vectors using quantitative PCR and found that dbs were 
significantly more abundant in most organs studied. These advantages suggest that db 
vectors are good candidates for clinical gene therapy studies. One drawback of this in 
vivo study is that the kinetics of gene expression were not investigated. Transgene 
expression was measured only at 8 hours post transfection, therefore both short-term 
and long-term expression profiles of dbs are yet to be studied. 
Because of the unique structure of dbs, they are ideally suited to be linked with other 
functionally active molecules, which superpose the vectors with additional functions. 
One example is the MIDGE-TH1 vector, which is characterized by a covalently bound 
TH1-peptide to the single-stranded loop region of the db vector (Schirmbeck, König-
Merediz et al. 2001). Originally, this peptide was intended to improve nuclear vector 
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delivery. However, studies have shown that it instead induced a significantly 
improved humoral and cellular immune response, compared to plasmid or unmodified 
MIDGE
TM
. The potency of the MIDGE-TH1 vector can be further increased by the 
formulation of this vector with cationic pyridinium amphiphile SAINT-18 (Endmann, 
Baden et al. 2010, Endmann, Klunder et al. 2014, Endmann, Oswald et al. 2014). In 
addition to TH-1 peptide, db vectors have also been linked to other peptides containing 
proven or putative nuclear localization signals, including SV40 T-antigen, bovine 
herpes virus-1 VP8, and herpes simplex virus-1 VP22 (Zheng, Juhls et al. 2006).  
MIDGE-TH1 vectors have been tested for vaccination against various diseases. 
Optimal immune responses have been observed using MIDGE-TH1 vector designed 
against Leishmaniasis. Leishmaniasis is caused by Leishmania species, which are 
intracellular pathogens widespread over Africa, Asia, and South America. Currently 
there is no effective vaccine against any form of this disease. MIDGE-TH1 vector 
encoding the LACK antigen has been tested as novel DNA vaccine in susceptible 
Balb/c mice. Using a prime-boost vaccination regimen, this strategy was shown to 
confer highly effective protection against Leishmania infection in mice (Lopez-
Fuertes, Perez-Jimenez et al. 2002). Db vector are also used in vaccination to fight 
against feline immunodeficiency virus (FIV) infection in cats. FIV infection 
resembles human HIV infection in many ways and is therefore a suitable model to test 
vaccination strategies against infections with HIV. Cats vaccinated with a db vector 
encoding FIV envelope protein together with another db encoding feline IL-12 gene 
showed a high rate of protective immunity after challenge with FIV (Boretti, 
Leutenegger et al. 2000, Leutenegger, Boretti et al. 2000). 
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Db technology has also been used to combat cancer. One strategy is to use db vectors 
to express tumour-associated antigens (TAAs), and then induce a systemic immune 
response toward the TAAs as well as all tumour cells expressing those molecules. 
This strategy has been used to prevent relapses of Philadelphia chromosome positive 
(Ph
+
) acute lymphoid leukaemia (ALL) (Kochling, Prada et al. 2008). Tumour cells 
for Ph
+
 ALL express the BCR-ABL
P185 
fusion protein, which is responsible for the 
maligned phenotype of the affected cells. To evoke immune response against this 
molecule, mice were treated with db vectors encoding a peptide of 83 amino acids 
from BCR-ABL
 P185 
and GM-CSF, together with immunomodulator dSLIM
TM
. This 
treatment showed significant protection against a challenge with the syngeneic Ph
+
 
ALL cell line BM185, with 26% of mice not developing a tumour at all, while the rest 
mice developed tumour at significantly later stage (Kochling, Prada et al. 2008, 
Kochling, Rott et al. 2012). Another strategy that harnesses the immune system to 
treat cancer is to use cell-based therapies (Blattman and Greenberg 2004). The 
efficacy of db vectors and dSLIM
TM
 has also been reported for cell-based therapy in 
an ALL mouse model (Köchling, König-Merediz et al. 2003). This strategy has also 
been tested in a phase I/II clinical trial conducted in patients with metastatic tumours 
(Wittig, Marten et al. 2001). A tumour-specific immune response was observed and 
50% of the patients responded clinically to this therapy. Db vector has also been used 
in combination with chemotherapy to treat melanoma (Kobelt, Aumann et al. 2014). 
In a study led by Walther, it was shown that db vector induced high-level expression 
of hTNFalpha both in vitro and in vivo, and this led to sensitization of melanoma cells 
towards vindesine. In a melanoma mouse model, jet-injection gene transfer of db 
vector encoding hTNFalpha in combination with vindesine resulted in tumour growth 
inhibition and increased apoptosis. 
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Db vectors have been applied to a variety of diseases and models, and have been 
shown to be superior in many cases compared with corresponding plasmids. 
Importantly, these vectors were demonstrated to meet all demands of safety, as shown 
in both animal models and clinical trials. It is highly anticipated that this technology 




1.5 RNA Interference 
The phenomenon of double-stranded RNA (dsRNA) triggered silencing was 
discovered in 1998 by Fire and Mello (Fire, Xu et al. 1998). Before that, single-
stranded antisense RNAs or DNA oligonucleotides were used by researchers to inhibit 
gene expression. Antisense RNAs can reduce target gene expression by base pairing 
with the target RNA leading to a block of translation. Fire and Mello showed that long 
dsRNAs were more potent than traditional antisense RNA in Caenorhaditis elegans, 
and this ground-breaking work overturned the contemporary view. However, while 
long dsRNAs trigger specific gene silencing in lower eukaryotes, they evoke target 
unspecific interferon responses leading to apoptosis in mammalian cells. Only the 
discovery by Tuschl and co-workers, that short or small interfering RNAs (siRNA) 
can trigger specific gene silencing even in mammalian including human cells, paved 
the way for therapeutic applications of this technology (Elbashir, Harborth et al. 
2001).  
1.5.1 The biogenesis of siRNAs and miRNAs 
It is crucial to understand the biogenesis of the small RNAs before we can apply the 
knowledge to the development of RNAi-based therapies. Figure 6 shows the 




Figure 6. The miRNAs and siRNAs biogenesis pathways in mammals.  
Pri-miRNAs are trimmed by Drosha-DCGR8 complex into ~70 nt precursors, termed 
pre-miRNAs. pre-miRNAs are associated with exportin 5 and will be exported into 
the cytoplasm, where they will be processed into miRNA-miRNA* duplexes by Dicer. 
Guide strand will later be incorporated into RISC complex and direct RISC to mRNA 
target for post-transcriptional silencing. Long dsRNAs are directly processed by Dicer 
in the cytoplasm into small interfering RNAs (siRNAs). Within the pre-RISC 
complex, strand selection occurs and the passenger strand will be cleaved by the AGO 
protein. Then, the mature RISC which contains an AGO protein and the guide strand 
associates with the target mRNA for cleavage. Adapted from Davidson BL et al. 2011 
 
MiRNAs are usually processed from longer endogenous transcripts, termed pri-
miRNAs. The transcription of miRNA genes are mediated by RNA polymerase II 
(Krol, Loedige et al. 2010). The pri-miRNAs fold into hairpins and act as the 
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substrates for Drosha and Dicer, two enzymes from the type III RNase family. The 
mature miRNAs are then loaded as guides to form the RNA-mediated silencing 
complexes (RISCs). Through the base pairing with the ‘seed region’ and supported by 
the 3’ supplementary region, the mature miRNA guides the RISC to the target mRNA. 
The region within the target mRNA which is complementary to the miRNA seed is 
termed miRNA recognition or response element (MRE). MREs are typically found in 
the 3’ UTRs of mRNA targets. MiRNAs are usually not perfectly complementary 
with the targets, therefore the bioinformatics prediction of miRNA targets is very 
challenging. MiRNAs regulate the expression of the target genes through several 
different mechanisms. Resources showed that in some cases miRNAs repress the 
translation of the targets by binding (Thermann and Hentze 2007), while some other 
studies indicate miRNAs direct target mRNA to cytoplasmic processing bodies, after 
which deadenylation and degradation of the mRNA occurs (Eulalio, Behm-Ansmant 
et al. 2007, Guo, Ingolia et al. 2010). Bhattacharyya SN and colleagues also reported 
that the repression mediated by miRNA is reversible, repression can be relieved when 
cells are subjected to different stress conditions (Bhattacharyya, Habermacher et al. 
2006). 
SiRNAs are ~17-24 nt in length and harbour 5’ PO4 and 3’ OH groups. Only if the 
antisense siRNA is selected as the guide, a silencing competent RISC is formed. The 
strand that is not selected for RISC, termed the passenger strand, will be degraded 
(Matranga, Tomari et al. 2005). Thermodynamic properties of the siRNA duplex 
determine which strand will be selected (Khvorova, Reynolds et al. 2003). siRNAs 
generally show perfect complementarity to their targets, and mediate the cleavage of 
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the target mRNA which occurs between positions 10 and 11 from the 5’ end of the 
guide strand binding site (Zamore, Tuschl et al. 2000). 
Different strategies have been developed for harnessing the RNAi pathways for gene 
therapy. Recombinant inhibitory RNAs were designed to mimic pri-miRNAs and pre-
miRNAs (miRNA precursors that have been processed by Drosha), whereas chemical 
synthesized RNA oligonucleotides are designed to mimic the substrates for Dicer 
cleavage. For both of the above strategies, specific gene silencing mediated by RISC 
can be achieved, but the exogenous RNAs enter the biogenesis pathway at different 
steps. Recombinant inhibitory RNAs are usually delivered by plasmids or viral 
vectors, which trigger longer lasting effects compared with exogenously applied RNA 
oligonucleotides, for which the silencing effect is usually transient. 
1.5.2 Strategies for the design of inhibitory RNAs 
The most straightforward method to harness the RNAi pathway is to directly use 21-
22 nt siRNA duplexes in vitro. The RNA duplex can be introduced into the target 
cells by different methods in vitro, such as transfection or electroporation. For in vivo 
applications, chemically modified oligonucleotides are often used to improve siRNA 
stability and efficacy. These oligonucleotides can be delivered in vivo with the help of 
various carriers, including liposomes, nanoparticles (polymers), and antibodies (Li 
and Rana 2014). Once the RNA enters the cell, the guide strand will be loaded into 
the RISC and trigger the silencing of the target. Another option is to use longer 
dsRNAs, usually 25-27 nt long, these RNAs are called ‘Dicer-ready siRNAs’ or Dicer 
substrate siRNAs, which will serve as the substrates for Dicer cleavage. Some studies 
suggest that ‘Dicer-ready siRNAs’ show greater potency than the shorter siRNAs do 
(Kim, Behlke et al. 2005, Siolas, Lerner et al. 2005). These dsRNAs can be delivered 
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into cell lines using transfection or electroporation technologies. However, alternative 
packaging may be necessary if the RNAs are to be delivered into primary cells or for 
in vivo applications. 
Alternatively, small hairpin RNA (shRNA) siRNA precursors or miRNA precursors 
can be transcribed endogenously from a delivered DNA vector. Once delivered, the 
RNAi triggers can be transcribed as sense and antisense sequences which are 
connected by a loop sequence. The structure of the transcribed RNA is similar to the 
pri-miRNAs or pre-miRNAs and can be recognized by the Drosha-DGCR8 complex 
for processing. The hairpin is exported into the cytoplasm after Drosha cleavage, and 
will be further processed by Dicer and then loaded into the RISC. Guide strand then 
directs RISC to mRNA target whereas the passenger strand is degraded. 
It should be emphasized that for shRNAs, though they are designed to mimic pre-
miRNAs, they do not always reflect Drosha cleavage products (Boudreau, Monteys et 
al. 2008). Furthermore, not all shRNAs can be efficiently exported, especially when 
they do not have the typical 3’ dinucleotide overhang. Nuclear accumulation of 
shRNAs is toxic and can be lethal when the shRNA is expressed in vivo (Grimm, 
Streetz et al. 2006, McBride, Boudreau et al. 2008). In other circumstances, even 
though the shRNA might be able to be exported by exportin 5, the nuclear export 
pathway can be saturated when the expression level of the shRNA is exceptionally 
high. To alleviate this saturation, a weaker promoter can be used to reduce the 
transcription, or alternatively a miRNA stem can be added to the shRNA to enhance 




1.5.3 Strategies for the design of miRNA inhibitors 
MiRNA dysregulation was shown to contribute to many human diseases, including 
cancer, viral infection, cardiovascular diseases, and inflammatory diseases (Li and 
Rana 2014). Efficient and specific targeting of aberrantly expressed miRNAs in these 
diseases may serve as a novel therapeutic strategy. Many different approaches have 
been developed during the last decade for miRNA inhibition, including vector-based 
strategies, antisense oligonucleotides (ASOs), and small-molecule inhibitors. 
Vector-based strategies use viral or non-viral vectors to express RNAs containing 
multiple artificial miRNA binding sites (Ebert, Neilson et al. 2007). These RNAs, 
once expressed in the target cells, can compete with the endogenous miRNA targets 
for binding, thereby inhibit the function of the miRNA. These strategies are widely 
used in vitro to study miRNA functions. However, their utility in vivo is limited thus 
far. Recent studies also indicate endogenous large non-coding RNAs can serve as 
natural inhibitors of cellular miRNAs and up-regulate the expression of miRNA target 
genes (Cesana, Cacchiarelli et al. 2011, Tay, Kats et al. 2011). 
Compared with vector-based strategies, the ASO technology represents a more 
straightforward approach to inhibit miRNA function. ASOs are usually fully 
complementary to the targeted miRNAs thereby blocking binding between the 
miRNAs and their endogenous targets. Because natural DNA or RNA 
oligonucleotides are sensitive to degradation by serum nucleases, ASOs are usually 
chemically modified to improve the stability and binding affinity. Commonly used 
modifications include 2’-O-methyl (2’-OMe) modifications (Meister, Landthaler et al. 
2004),  locked nucleic acid (LNA) modifications (Orom, Kauppinen et al. 2006), and 
phosphorothioate modifications of the oligonucleotides (Krutzfeldt, Rajewsky et al. 
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2005). Many researchers incorporate two or more modifications into the ASOs to 
generate more potent molecules. Antogomirs
TM
 developed by Krutzfeldt et al. 
represents a notable example and the efficacy of this approach has been demonstrated 
in various studies (Krutzfeldt, Rajewsky et al. 2005, Ma, Reinhardt et al. 2010). 
Besides vector-based strategies and ASOs, conventional small molecules are also 
being developed for miRNA inhibition. Small molecules that can specifically inhibit 
miRNA expression are generally identified via reporter-based systems for compound 
library screening. One example is azobenzene, a compound selected from the Library 
of Pharmacologically Active Compounds (Sigma-Aldrich), was shown to specifically 
affect miR-21 expression (Gumireddy, Young et al. 2008). Similarly, small-molecule 
inhibitor as well as activator of miR-122 have also been reported (Young, Connelly et 
al. 2010).  Different from ASOs or long antisense RNA transcripts, small molecules 
modulate target miRNA expression mainly through transcriptional regulation. 
Currently the therapeutic potential of these miRNA modifiers are still limited by their 
high EC50 values and the lack of information on their direct targets. 
The potential off-target effects of miRNA therapeutics are a major concern because 
they may cause toxic phenotypes. These can be divided into two main categories: 
hybridization-associated and hybridization-independent off-target effects. Many 
miRNAs belong to miRNA families which have very similar seed regions, such as let-
7 and miR-17 families. Currently, the miRNA inhibitors are usually designed to be 
perfectly complementary to the targets. Under physiological conditions, these 
inhibitors are generally unable to distinguish the target miRNA and other miRNAs 
from the same family, especially those with the same seed sequences. Previous study 
by Li et al. already showed that a 2’-OMe-modified miR-93 inhibitor was able to 
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inhibit other members from the same miRNA family, such as miR-106b (Li, Yang et 
al. 2011). The ability of miRNA inhibitors to cross-inhibit other molecules with 
similar sequences suggests that caution is needed for the development of therapeutics 
targeting a specific miRNA. One good strategy would be targeting the miRNAs at 
their precursor stage. A pioneer study by Kloosterman et al. reported that miRNA 
biogenesis and processing could be efficiently inhibited in an miRNA-specific manner 
by morpholinos in zebra fish embryos (Kloosterman, Lagendijk et al. 2007). This 
strategy may help to overcome the off-target effects caused by targeting only the 
mature miRNAs, where there is very limited flexibility for targeting individual 
miRNAs from the same family. Besides hybridization-associated off-target effects, 
miRNA inhibitors and their carrier proteins may also be detected by both the innate 
and adaptive arms of the mammalian immune system. The immunostimulatory off-
target effects are major toxicological concerns for oligonucleotide therapeutics. Both 
RNA and DNA nucleotide sequences can be detected by pattern recognition receptors 
(TLR) expressed by cells of the innate immune system. It is also known that chemical 
modifications of the oligonucleotides induce sequence-independent toxicity in vivo 
(Bennett and Swayze 2010). These observations suggest that we need careful 
evaluation of the miRNA inhibitor design to develop a robust but less toxic molecule, 
and this should be addressed in a case-by-case manner. 
In the last decade, substantial progress has been achieved in the field of RNAi, 
molecular processes driving small RNA biogenesis have been elucidated, and 
researchers already started harnessing this powerful tool for the development of novel 
therapeutic strategies. Although some hurdles remain before the RNAi technologies 
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can be used in the clinical setting, recent trails indicated a broad spectrum of 




1.6 Technologies for nucleic acid detection 
A number of different strategies have been developed over time to identify unique 
nucleic acid sequences. Nucleic acid-based detection assay can be roughly classified 
into two categories: i) direct target probing with antisense oligonucleotides; and ii) 
target amplification, or combination of both, including TaqMan-probe-based rtRT-
PCR. 
1.6.1 Target probing-based nucleic acid detection methods 
Almost all probing-based detection technologies are based on the ability of 
complementary nucleic acid strands to form stable hybrids. Adhering to the Watson-
Crick rules of base pairing, complementary strands anneal to each other. The stability 
of the hybrids is gauged by the melting temperature (Tm), which is affected by the 
nucleotide composition and sequence of the nucleic acid, ionic concentration, length 
of the complementary sequence and mismatches between the strands. 
To generate a signal that can be easily detected, many reporters were developed and 
were conjugated with the probe molecules. Commonly used reporters include 
radioisotopes, fluorophores, enzymes and haptens. Radioisotopes were the first to be 
used in research; however, they have lost their popularity due to the limited half-life 
and safety concerns. Fluorophore and enzyme labelling soon replaced radioisotopes, 
but the conjugation with these macromolecules may sometimes compromise the 
performance of the probe. Low molecular weight compounds for which high affinity 
capture systems exist are also used to label probes. One of the most widely used 
system is biotin-streptavidin. The sensitivity and specificity of hybridization based 
method can be increased by the branched DNA (bDNA) technology. First developed 
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to quantify the viral load for HIV and Hepatitis, this method combined probe 
hybridization step with an additional signal amplification step (Chernoff, Miner et al. 
1997, Wilber 1997). Unlike target amplification methods such as PCR, bDNA signal 
amplification method can quantify target nucleic acid at physiological levels. Also, 
because signal amplification requires 30 or more probes to bind to the target, this 
method is very specific (Iqbal, Chambers et al. 1999). 
1.6.2 Target amplification-based nucleic acid detection methods 
The major drawback for hybridization-based quantification methods is that they are 
limited in terms of sensitivity. Detection sensitivity also varies for different targets. 
Although the development of signal amplification processes (such as the bDNA 
technology) greatly improved hybridization-based detection, these systems are labour-
intensive and require the services of highly skilled personnel. Target amplification-
based methods which are based on the technology of polymerase chain reaction 
(PCR), on the other hand, are much more sensitive and straightforward. 
Taq polymerase, which is commonly used for PCR amplification, also has a 5’ 
nucleolytic activity (Iqbal, Mayo et al. 2000). Hydrolysis probes were later designed 
based on the nucleolytic activity of the PCR polymerase. Typically, a dual-labelled 
fluorogenic probe can be designed to bind to the target nucleic acid. Two fluorophores 
were conjugated at each end of the probe, and the emission intensity of the first 
reporter can be quenched by the second. The quenching is distance dependent and as 
the DNA polymerase hydrolyses the fluorogenic probe hybridized to the amplicon, 
the fluorophore is released and the fluorescence intensity increases. The increase in 
fluorescence intensity is directly proportional to the abundance of the templates. 
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TaqMan probes developed by TibMolBiol are the most commonly used hydrolysis 
probes (Fitzmaurice, Glennon et al. 2004). 
Based on the basic PCR technology, real-time PCR and real-time reverse transcription 
PCR were later developed, which have dramatically changed the field of gene 
expression measurement. Real-time PCR collects data during the PCR process, thus 
combining amplification and detection in a single step (Wong and Medrano 2005). 
Signal detection is achieved by using fluorescent molecular reporters that correlate 
PCR product concentration to fluorescence intensity. A summary of different 
detection chemistries for real-time PCR is shown in Table X. Real-time PCR exhibits 
many advantages over other parallel methods for gene expression quantification. 
Real-time PCR detection is accurate over a dynamic range of 7 to 8 orders of 
magnitude (Rasmussen, Morrison et al. 1998). The data collected from real-time PCR 
is usually more reliable than end point assays such as probe hybridization and band 
densitometry (Schmittgen, Zakrajsek et al. 2000). The discrimination of mRNAs is 
also efficient for real-time RT-PCR, and much less RNA material is required for the 
detection. Real-time PCR technology is therefore considered as the gold standard for 










Two PCR primers, one 
specific probe 
Yes High 
Hydrolysis probes Two PCR primers, one 
specific probe 
Yes High 




Table 2. Characteristics of different real-time PCR detection chemistries. 
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Although real-time PCR technology is widely used in many laboratories, it shows 
limited efficiency in capturing small RNAs, which have become the interest of 
research in many fields. Small RNAs such as miRNAs, are too short to provide 
sufficient complementary for conventional linear real-time PCR primers to hybridize 
with. Chen et al. developed a stem-loop primer-based RT-PCR technique for small 
RNA detection (Chen, Ridzon et al. 2005). This method uses a stem-loop reverse 
transcription primer to capture the 3’ end of the target small RNA due to an additional 
stabilization of the formed duplex via base stacking along the helix, thus significantly 
reduces the complementarity needed. It has been shown that this strategy can detect 
target small RNA with high sensitivity and specificity. However, the stem-loop 
primer-based RT-PCR method requires an individual TaqMan probe for each small 





1.7 Aims of the study 
In this study we explored to use novel dumbbell vectors for both non-coding and 
coding RNA expression. For non-coding RNA expression we designed vectors to 
express shRNA, natural miRNA, as well as antisense miRNA inhibitors. In order to 
accurately and cost-effectively monitor the expression of these small RNAs, we first 
developed a new TaqMan-based RT-PCR method for small RNA detection. This 
detection method was used later for the quantification of all small RNAs expressed 
from both dumbbell vectors and plasmids. We investigated molecular features that 
would improve dumbbell vector and this was done for both coding and non-coding 
RNA expression dumbbells. In most cases, pathogenesis involves dysregulation of 
multiple genes, and in order to provide treatment, we usually need to increase the 
expression of certain genes, and inhibit the expression from some others at the same 
time. With the dumbbell development, we tried to improve the vector for both coding 
and non-coding RNA expression, and these expression vectors can be used together to 
provide treatment in a clinical scenario.  
The specific aims of this study include: 
1. To develop a universal stem-loop primer-based TaqMan RT-PCR technology for 
small RNA detection and compare the sensitivity and specificity of this new 
method with state-of-the-art techniques. 
2. To design novel db vectors for small RNA expression and investigate the 
performance of the vectors in cell culture. 
3. To investigate molecular features that might improve db vectors for protein-
coding gene expression and test the vectors in immortalized cells as well as 
human primary cells.  
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45 
 
2.1 The universal TaqMan-based RT-PCR protocol 
2.1.1 RNA purification 
RNA from human tissue culture cell lines HEK293T and Jurkat was purified using 
TRIzol (Invitrogen) according to the manufacturer’s recommendations. Briefly, cells 
were homogenized by a suitable volume of TRIzol reagent, and incubated at room 
temperature for 10 min. After the incubation 0.2 volume of chloroform was added to 
the homogenous mixture. Chloroform was mixed with TRIzol reagent by vigorous 
shaking for 30 s. Then the mixture was incubated on ice for 15 min. Phase separation 
was achieved by centrifugation at 12,000g using a benchtop centrifuge for 15 min at 
4 °C. Then the upper aqueous phase was carefully transferred into a new tube. Nucleic 
acids were precipitated by addition of 0.7 volume of isopropanol and incubated at -
20 °C for 30 min. Then the precipitated nucleic acids were pelleted by centrifugation 
at 12,000g for 10 min at 4 °C. The pellets were washed twice by 70% ethanol, dried 
and then dissolved using an appropriate volume of nuclease free water (Invitrogen). 
RNA concentration was measured using NanoDrop spectrophotometer (Thermo 
Scientific).  
2.1.2 Reverse transcription and real-time PCR 
Various RNA templates used in this study, including double-stranded miRNA mimics 
(Applied Biosystems/Ambion), siRNA GFP22 (Qiagen), single-stranded synthetic 
mature miRNAs (Thermo Scientific/Dharmacon), and in vitro transcribed miRNA 
precursors, were serially diluted for reverse transcription reactions. Reverse 
transcription reaction was set up as shown in Table 1. 
Component Final concentration 
Stem-loop RT primer 50 nM 
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RT buffer 1x 
dNTP 0.25 mM each 
MultiScribe reverse transcriptase 25 Units 
RNaseOUT 3.8 Units 
RNA Various amount, 2.5 L 
 
Table 3. Reaction set up for reverse transcription. 
 
The 7.5 L reaction mixture was then incubated in the GeneAmp 9700 thermal cycler 
(Applied Biosystems) at 16 °C for 30 min, 42 °C for 30 min, 85 °C for 5 min, and 
kept at 4 °C. Then 1.33 L of the 7.5 L reverse transcription reaction was used as the 
templates for real-time PCR. For real-time PCR reaction, templates were mixed with 
1x TaqMan Universal PCR Master Mix (Applied Biosystems), 0.8 M universal 
TaqMan-based probe (FAM-MGB design), 1.5 M forward primer, and 0.7 M 
reverse primer. The real-time PCR was performed using the 7900HT Fast Real-Time 
PCR system (Applied Biosystems). All real-time PCR reactions were run in duplicate 
or triplicate. When RNA targets were detected using commercial kits (Applied 
Biosystems), instructions from the manufacturer were followed. 
2.1.3 RNA targets, primers and probes 
RNA targets used in this study are listed in Table 2. 








Mature miR-133b UUUGGUCCCCUUCAACCAGCUA 
Mature miR-146a UGAGAACUGAAUUCCAUGGGUU 
 
Table 4. Target RNA sequences used for the stem-loop primer-based universal 
TaqMan RT-PCR protocol. 
 
For miRNA precursors, the full-length precursor genes (according to miRBase 
http://mirbase.org/) including the upstream T7 promoter sequence and a BamHI site at 
the 5’ end, the SP6 promoter sequence and a HindIII site at the 3’ end were 
synthesized by gene synthesis (GeneArt, Applied Biosystems). For RNA in vitro 
transcription, the synthesized genes were PCR amplified from the standard gene 
synthesis vector pMA-T. PCR fragments were digested with HindIII and purified by 
PCR purification kit (Qiagen). The purified DNA served as the template for in vitro 
transcription. In vitro transcription was performed using T7 RNA polymerase 
(Thermo Scientific/Fermentas) and related reagents from Fermentas according to the 
manufacturer’s instructions. RNA transcripts were purified using TRIzol reagent and 
analyzed by 10% denaturing polyacrylamide gel electrophoresis. The complete 
synthesized sequences for miR-133b and miR-146a precursor genes are listed in Table 
3. 
 















Table 5. Gene synthesized sequences for miRNA precursors. 
 
All stem-loop reverse transcription primers, PCR primers are listed in Appendix I. 




2.2 Design of small RNA dumbbells 
The shRNA expression dbs were designed based upon previous work by Teo (2011) 
and Tan (2012). All shRNAs were designed to target firefly luciferase gene, and the 
sequences were obtained from a previous study by MOLOGEN (Oswald and Schroff 
2006). For miRNAs expressing dbs as well as shRNA db with miR-stem, the 
precursor sequences of miR-30 and miR-125b used in this study were obtained from 
miRBase (accession: miR-30 MI0000088; miR-125b MI0000446). For miRNA 
antagonist expressing dbs, we used the bioinformatics tool foldanalyze which is 
implemented into the software platform HUSAR to scan the antisense RNA structure 
space (length fractions of 30 or 35 nt) that can be directed against miR-21 and its 
precursors. The program foldanalyze is based on the RNA secondary structure 
prediction tool mfold. Four antagonist sequences against miR-21 with different 
structures were selected. To create dbs with nuclear targeting sequences (minimal 
SV40 and full-length SV40) derived from Simian Virus 40, full SV40 enhancer 
sequence was obtained from RefSeq database (accession: NC_001669). The 72 bp 
tandem repeat minimal SV40 enhancer sequence was synthesized by gene synthesis 
(GeneArt, Applied Biosystems). Prediction of putative transcriptional factor binding 
sites were based upon a combination of literature review and bioinformatics 
prediction using the algorithm MATCHTM (Kel, Gossling et al. 2003). The 237 bp 
full-length SV40 enhancer sequence was amplified by PCR using pGL3-control 




2.3 Production of small RNA dumbbells 
2.3.1 Overview of the production strategies 
Two different strategies were developed to produce the small RNA expression dbs. 
Originally the ELAN loop-ligation-based strategy was used: vector was assembled 
from three independent parts, namely the loop on the 5’ end, the promoter duplex, and 
the shRNA coding DNA oligonucleotide. Oligonucleotides forming the three units 
were annealed to form pre-designed 5’ or 3’ sticky ends, and then molecules were 
ligated to generate the db vector. Properly ligated dbs were selected by exonuclease 
treatment. 
We next developed another PCR-ligation-based method because with the original 
method, the db length was limited by the current technology of oligonucleotide 
synthesis. For example, when we introduced the nuclear targeting sequences, we had 
to anneal another pair of oligos, and the three-part ligation reaction became a four-part 
ligation reaction. Intermolecular ligation was not very efficient and therefore the 
conversion yield of the ligation-based method was not very high. In the PCR-ligation-
based method, we used primers to amplify the promoter region and introduce the 
restriction sites. To increase the ligation efficiency, we adopted the nicking enzyme 
ligation strategy as shown by Taki et al. to introduce the loop at the 5’ end (Taki, Kato 
et al. 2004). PCR amplified DNA fragment was digested by corresponding nicking 
enzyme and conventional restriction enzyme at the same time, and then was ligated to 
the shRNA-coding hairpin DNA template. In this case, the final ligation step was 
between two molecules, and was therefore more efficient. An illustration of the 




Figure 7. Production strategies for small-RNA dbs.  
There are four major steps for the synthesis of the small-RNA db vectors. In the first 
step the mH1 promoter is either amplified by PCR or synthesized by annealing of 
oligonucleotides. Proper nicking enzyme (NE) and conventional restriction (RE) site 
are introduced into the sequence. The second step is the digestion of the promoter 
DNA sequence by the corresponding nicking enzyme and restriction enzyme. Then 
the digested DNA is first purified, and annealed together with the hairpin DNA 
template oligo. Neutralizing oligo and column purification step were added as 
optimization procedures. In the annealing step both the loop at the 5’ end of the 
promoter and the DNA template form the correct structure. Then the two parts are 
ligated by the addition of T4 DNA ligase and essential buffers. The final step properly 
ligated Dbs are selected by exonuclease treatment and the vectors are purified by 
standard DNA purification techniques. 
 
 
2.3.2 Annealing of oligonucleotides 
For self-hybridizing oligonucleotides, including shRNA-coding DNA hairpins and 
loop oligos, annealing was mediated by heating 500 pmol of oligo sequences in 10 L 
of hybridization buffer at 95 °C and then chilling on ice immediately. For the 
hybridization of two oligonucleotides, synthesized DNA oligos were first dissolved in 
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nuclease-free distill water (Invitrogen) to a concentration of 100 M. 500 pmol of 
both strands were annealed in 10 L hybridization buffer by heating in boiling water, 
and then gradually cooling down to room temperature. 
10X Hybridization buffer: 
Reagent Final Concentration 
NaCl 1 M 
MgCl2 100 mM 
Tris/HCl pH 7.4 200 mM 
 
2.3.3 Construction of pSuper-mH1, pSuper-mH1-mSV40, and pSuper-mH1-
fSV40 
To amplify and preserve the minimal H1 promoter sequence, we cloned the minimal 
H1 promoter into pSuper plasmid (Oligoengine). pSuper is a vector specially designed 
for small RNA expression, for which the full length H1 promoter for transcription is 
used. We replaced the H1 promoter with the minimal H1 promoter to construct 
pSuper-mH1. Full-length H1 promoter was cut out from the plasmid by double 
digestion using EcoRI and BglII restriction enzymes. DNA was loaded on the 1.5% 
agarose gel for electrophoresis and the plasmid backbone was gel purified using gel 
purification kit (Qiagen). Annealed minimal H1 promoter was amplified by PCR 
using primers that introduced EcoRI and BglII restriction sites. The PCR fragment 
was digested with corresponding enzymes and then purified by PCR purification kit 
(Qiagen). Purified plasmid backbone and minimal H1 promoter fragment were ligated 
using T4 DNA ligation kit (Fermentas). Ligation mixture was transformed into TOP10 
Chemically Competent E. coli (Life Technologies) and plated on ampicillin agar 
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plates. Colonies were screened by colony PCR and restriction mapping. Positive clone 
of pSuper-mH1 was finally confirmed by sequencing.  
pSuper-mH1-mSV40 and pSuper-mH1-fSV40 constructs were made by fusing the 
enhancer sequences to the 5’ end of the minimal H1 promoter. Minimal and full-
length SV40 enhancer sequences were amplified by PCR and cloned into the SacI and 
EcoRI sites in the pSuper-mH1 plasmid. Positive clones were confirmed by 
sequencing.  
2.3.4 PCR amplification of promoter or enhancer-promoter sequences 
The minimal H1 promoter or SV40 enhancer-promoter was amplified by PCR using 
primers introducing Nb.Bpu10I nicking site and BamHI restriction site at 5’ and 3’ 
end, respectively. Taq polymerase and related reagents from Fermentas were used for 
the PCR reaction following the manufacturer’s instructions. Primers were designed 
using Primer Express (Applied Biosystems) software with the Tm of the annealing at 
58~60 °C. 
2.3.5 Enzymatic Ligation Assisted by Nuclease (ELAN) reaction and exonuclease 
treatment 
To facilitate correct ligation between the molecules and inhibit unwanted 
homodimer/heterodimer formation, we adopted the Enzymatic Ligation Assisted by 
Nuclease (ELAN) technique that has been described by Cost (Cost 2007). The 
simultaneous ligation and digestion design could destroy the by-products while the 
correctly ligated dumbbell vectors were left unaffected because no palindromic 
restriction sites were formed. T7 DNA polymerase exonuclease treatment was carried 
out after the ligation step to degrade the remaining oligos and unligated DNA 
fragments. Successfully ligated dumbbell vectors remained intact due to their 
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covalently closed structure. Detailed reaction setups were summarized in Table 4. All 
reactions were performed in Thermomixer heat block (Eppendorf). 
 Amount Condition 
Digestion 
Promoter/enhancer-promoter 10 pmol 
37°C incubation for 4 h and heat 
inactivation at 80°C for 5 min 
Nb.Bpu10I* 10 Units 
BamHI 1 FD Unit 
FD buffer 1x 
Annealing 
Digestion mixture  
Incubate in boiling water and let the 





22°C for 4 h to overnight and heat 
inactivation at 85 °C for 5 min 
Hairpin DNA template 10 pmol 
BamHI 1 FD Unit 
BglII 1 FD Unit 
T4 DNA ligase 20 Units 
ATP 1 mM 
FD buffer 1x 
Exonuclease treatment with additional digestion 
BamHI 1 FD Unit 
37°C incubation for 1 h and heat 
inactivation at 85°C for 5 min 
BglII 1 FD Unit 
T7 DNA polymerase 10 Units 
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FD buffer 1x 
 
Table 6. Reaction setups for the generation of small RNA Dbs using the PCR-
ligation strategy.  
* Nb.Bpu10I nicking enzyme is recommended to be used in Fermentas Buffer R; 
Fermentas FD buffer was used for db generation after consulting the Fermentas 
technical support. 
 
Dbs were purified after the exonuclease treatment either by PCR purification kit 
(Qiagen) or phenol/chloroform extraction. Samples after each step were analyzed on 
10% polyacrylamide gel. Purified DNA was dissolved in nuclease-free water and the 





2.4 Generation of luciferase expression constructs 
2.4.1 Generation of miRNA sensors 
To monitor the expression levels of both endogenous and ectopic miRNAs, we made 
miRNA sensor constructs based on previous studies (Beillard, Ong et al. 2012, Xie, 
Ameres et al. 2012). Three tandem artificial miRNA binding sites were designed and 
synthesized as oligonucleotides. The sense and antisense strands were annealed in 1x 
hybridization buffer and cloned into the pMIR-Report (Promega) vector using SacI 
and HindIII restriction sites. Sensors for miR-125b and miR-21 were constructed and 
correct clones were verified by sequencing. 
2.4.2 Generation of luciferase intron enhancer variants 
To study the function of synthetic intron and SV40 enhancer, we made several 
constructs based on the pGL3-control vector. We first synthesized the 132 bp chimeric 
human -globin mini-intron by gene synthesis (GeneArt, Applied Biosystems), and 
then cloned it into the pGL3-control plasmid using HindIII and NcoI sites. pGL3-
control plasmid uses SV40 promoter to trigger the expression of luciferase gene, and 
there is SV40 enhancer element at the 3’ end of the expression cassette. We deleted 
this enhancer sequence by digestion of the vector with XbaI and BamHI. By doing 
this we also deleted the SV40 late poly(A) signal, therefore we PCR amplified this 
region and put it back to the digested construct using the same restriction sites. We 
performed the cloning procedure for both original pGL3-control plasmid and the 
pGL3-control with the chimeric intron. To avoid confusion, we renamed all the 
constructs based on the elements they have, as listed in Table 5: 




pGL3-control+chimeric intron int-luc-enh 
pGL3-control+enhancer deletion luc 
pGL3-control+chimeric intron+enhancer deletion int-luc 
 




2.5 Production of protein-coding dumbbells 
Two different methods were used to produce large protein-coding dumbbells, namely 
the PCR-based method and the ELAN loop-ligation method. In the PCR-based 
method, gene expression cassette was first amplified by PCR using primers 
introducing the Nb.Bpu10I nicking site at both the 5’ and 3’ end. Purified PCR 
fragment was then digested with the Nb.Bpu10I nicking enzyme. After digestion, the 
DNA was annealed to form the loop structure and then T4 DNA ligase and buffer was 
added to ligate the loops on both ends. Successfully ligated dumbbells were then 
selected by exonuclease treatment. Detailed protocol is shown in Table 6: 
 
 Amount Condition 
Digestion 
PCR amplified gene expression 
cassette 
5 pmol 
37°C incubation for 4 h and heat 
inactivation at 80°C for 5 min Nb.Bpu10I 10 Units 
Buffer R 1x 
DNA Purification 
Annealing 
Purified DNA  
Incubate in boiling water and let the 
water cool down to room temperature 
Ligation 
Annealed gene expressing 
cassette 
5 pmol 22°C for 4 h to overnight and heat 
inactivation at 85 °C for 5 min 
T4 DNA ligase 40 Units 
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ATP 0.5 mM 
Ligation buffer 1x 
Exonuclease treatment with additional digestion 
T7 DNA polymerase 10 Units 37°C incubation for 1 h and heat 
inactivation at 85°C for 5 min Ligation buffer 1x 
 
Table 8. Reaction setups for the generation of large protein-coding dbs using the 
PCR-based strategy. 
 
In the ELAN loop-ligation method, the gene expression cassette was either amplified 
by PCR, or directly cut out from parental plasmid. Loops were designed following the 
strategy as shown in the ELAN reaction in the small RNA expressing dbs production 
method. 50 times more loops were added in the ligation reaction to ensure that most 
of the gene expressing cassettes could be capped. By-products such as loop dimers 
were cleaved by the restriction enzymes and were destroyed during the exonuclease 
treatment. Detailed setups of the reaction are shown in Table 7. 
 Amount Condition 
Digestion 
Parental plasmid 1 pmol 
37°C incubation for 4 h and heat 
inactivation at 80°C for 5 min 
Restriction enzyme A 1 FD Unit 
Restriction enzyme C 1 FD Unit 
FD buffer 1x 
ELAN reaction 
Digested DNA 1 pmol 22°C for 4 h to overnight and heat 
inactivation at 85 °C for 5 min Loop-1 50 pmol 
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Loop-2 50 pmol 
Restriction enzyme A 1 FD Unit 
Restriction enzyme B 1 FD Unit 
Restriction enzyme C 1 FD Unit 
Restriction enzyme D 1 FD Unit 
Restriction enzyme E 1 FD Unit 
T4 DNA ligase 20 Units 
ATP 1 mM 
FD buffer 1x 
Exonuclease treatment with additional digestion 
Restriction enzyme A 1 FD Unit 
37°C incubation for 1 h and heat 
inactivation at 85°C for 5 min 
Restriction enzyme B 1 FD Unit 
Restriction enzyme C 1 FD Unit 
Restriction enzyme D 1 FD Unit 
Restriction enzyme E 1 FD Unit 
T7 DNA polymerase 10 Units 
FD buffer 1x 
 
Table 9. Reaction setups for the generation of large protein-coding dbs using the 
ELAN loop-ligation strategy.  
In this strategy two restriction enzymes (A and C) were used to digest the parental 
plasmid. In this ELAN reaction, two additional enzymes (B and D) compatible with A 
and C, respectively, were added to the reaction to inhibit the formation of loop 
homodimers. Another restriction enzyme (E) was also added to digest the backbone of 
the plasmid. This enzyme (E) was usually a single cutter that cut the backbone region 
of the plasmid therefore it could be destroyed by the exonuclease treatment. All the 





2.6 Phenol/chloroform extraction 
Phenol/chloroform extraction was performed according to the following protocol: 
1. Add distilled water to DNA solution to make up the volume to 400 µL and transfer 
into an 1.5 mL reaction tube. 
2.  Add equal volume i.e. 400 µL of PCI. 
3. Vortex 30 s (to remove proteins) or 2 min (to remove agarose or acrylamide).  
4. Centrifuge 5 min at 12,000 rpm. 
5. Carefully transfer the complete upper aqueous phase that contains the nucleic acids 
without touching the interphase (if any) into a new reaction tube.  
6. Repeat steps 2 -5 twice. 
7. Add equal volume (400 µL) of CI, shake vigorously for 30 s.  
Note: vortexing will not mix the two phases efficiently.  
8. Centrifuge 1 min at 12,000 rpm. 
9. Carefully transfer the complete upper aqueous phase that contains the nucleic acids 
without touching the lower organic phase into a new reaction tube.  
10. Repeat steps 6-9 twice.   
11. Adjust the volume of the aqueous phase with distilled water to 400 µL. 
12. For ethanol precipitation add 1/10 i.e. 40 µL of the volume of sodium-, potassium, 
or ammonia- acetate buffer (pH 4.7 to 5.2).  
13. Add 2.5 volumes (e.g. 440 µL x 2.5 = 1100 µL) absolute ethanol and precipitate 
the nucleic acids at -20 °C for 30 min.  
14. Centrifuge 15 min, 4 °C, 12,000 rpm. Carefully discard the supernatant. 
15. Wash pellet using 70% ethanol (4 °C, diluted with nuclease-free water) 
16. Centrifuge again and discard supernatant. 
17. Dry pellet. For DNA use a speedvac centrifuge. RNA should be air-dried.  
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Buffers and solutions: 
PCI: Phenol (pH 8.0): Chloroform: Isoamylalcohol (25: 24: 1) 
CI: Chloroform: Isoamylalcohol (24: 1) 




2.7 DNA Polyacrylamide Gel Electrophoresis (PAGE) 
PAGE gel electrophoresis was performed according to the following protocol: 
1. Clean the glass plates and spacers thoroughly. Rinse the plates with deionized 
water and ethanol and set them aside to dry. 
2. Assemble the glass plates with spacers in gel caster.  
3. Prepare the gel solution with the desired polyacrylamide percentage according to 
the table below, which gives the amount of each component required to make 12 ml 
(sufficient for 2 Hoefer minigels of 1 mm thickness):  












8 3.2 7.6 1.2 200 10 
10 4.0 6.8 1.2 200 10 
12 4.8 6 1.2 200 10 
* 7M of urea was added when making denaturing polyacrylamide gels.  
4. Wear gloves. Work quickly after addition of TEMED to complete the gel before the 
acrylamide polymerizes.  
5. Immediately insert the appropriate comb into the gel, being careful not to allow air 
bubbles to become trapped under the teeth. Make sure that no acrylamide solution is 
leaking from the gel mold.  
6. Allow the acrylamide to polymerize for 60 minutes at room temperature.  
7. Remove gels from gel caster, carefully clean spilled gel from back of white plates 
and insert gels into Hoefer gelbox. Add running buffer and carefully pull the combs 
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from the polymerized gel.  
8. Use a syringe to flush out the wells once more with 1X TBE. Mix the DNA 
samples with the appropriate amount of gel- loading buffer. Load the mixture into the 
wells using a micropipette equipped with a drawn-out plastic tip. 
9. Connect the electrodes to a power pack, turn on the power, and begin the 
electrophoresis run. 
10. Run the gel until the marker dyes have migrated the desired distance. Turn off the 
electric power, disconnect the leads, and discard the electrophoresis buffer from the 
reservoirs.  
11. Detach the glass plates. Lay the glass plates on the bench. Use a spacer or plastic 
wedge to lift a corner of the upper glass plate. Check that the gel remains attached to 
the lower (white) plate. Pull the upper plate smoothly away. Remove the spacers.  
12. Stain gels with EtBr and analyze the gel using the Gel Doc system (Bio-Rad). 
Buffers and Solutions: 
Acrylamide:bisacrylamide (29:1) (30% w/v) (Bio-Rad) 
Ammonium persulfate (10% w/v) (Sigma-Aldrich) 
TEMED (Bio-Rad) 
10X TBE electrophoresis buffer: 
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Reagent Final concentration 
Tris 890 mM 
Boric acid 890 mM 
EDTA, pH 8.0 20 mM 
 
Gel loading buffer: 
Reagent Final concentration 
Urea 7 M 
Tris/HCl, pH 8.0 50 mM 
EDTA, pH 8.0 25 mM 
SDS 0.5% (w/v) 
Bromphenolblue Amount corresponding to a grain of sand 





2.8 Cell culture 
2.8.1 Maintenance of cell lines 
Human HEK293T and HepG2 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Invitrogen) supplemented with 10% v/v heat-inactivated Fetal 
Bovine Serum (Hyclone) and 1% penicillin-streptomycin solution (Invitrogen). 
Leukaemia Jurkat cells were grown in RPMI1640 media (Invitrogen) supplemented 
with 10% v/v heat-inactivated Fetal Bovine Serum (Hyclone) and 1% penicillin-
streptomycin solution (Invitrogen). Cells were kept in humidified incubator with 5% 
CO2, and were passaged by 80-90% confluency. 
2.8.2 Maintenance of primary cells 
Human peripheral blood mononuclear cells (PBMCs) were collected under informed 
consent from healthy donors in collaboration with Dr. Antonio Bertoletti’s lab. 
PBMCs were stimulated with 600 IU/mL recombinant Interleukin-2 (rIL-2, R&D 
Systems, Minneapolis, MN) and 50 ng/mL anti-CD3 OKT3 antibody (eBioscience, 





Transfection was performed using lipofection-based reagents Lipofectamine 2000 
(Invitrogen) and TurboFect (Thermo Scientific) following the manufacturer’s 
recommendations. In brief, cells were seeded in 24-well plate or 6-well plate the day 
before transfection at 70-80% confluence. On the day of transfection, an optimal 
amount of DNA was mixed with the transfection reagent in serum-free media. Opi-
MEM (Invitrogen) was used when transfection was performed using Lipofectamine 
2000 whereas DMEM was used when using TurboFect. DNA-lipid complex (DNA 
(g): transfection reagent (L) 1:2.5) was incubated at room temperature for 20 min, 
and then the mixture was added dropwise to the cells. Transfected cells were usually 




2.10 Nuclear extraction 
Nuclear extraction was performed according to the following protocol: 
1. Collect cells (5 x 106) in PBS by centrifugation (non-adherent) or scraping from 
culture flasks (adherent). Add feeder cells to make a bigger pellet. 
2. Wash cells twice with cold PBS.  
3. Remove and discard the supernatant and collect the cell pellet. 
4. Transfer the cells into a prechilled microcentrifuge tube. 
5. Gently resuspend cells in 1mL 1x Hypotonic Buffer by pipetting up and down 
several times. Incubate on ice for 15 minutes. 
6. Lyse cells by dounce homogenizer. First try 20 strokes, check lysis by Tryphan 
Blue stain under microscope, if necessary perform another 20 or more strokes. 
7. Centrifuge the homogenate for 10 minutes at 3,000 rpm at 4 °C. 
8. Transfer and save the supernatant. This supernatant contains the cytoplasmic 
fraction. The pellet is the nuclear fraction. 
9. Lyse the nucleus by freeze-thaw cycles 4 times using liquid nitrogen. 
10. Centrifuge for 30 minutes at maximum speed at 4 °C. Transfer supernatant 
(nuclear fraction) to a clean microcentrifuge tube. 
11. Aliquot and store at –80°C. The nuclear extracts are ready for assay. 
1X hypotonic buffer: 
Reagent Final concentration 
Tris/HCl, pH 7.4 20 mM 
NaCl 10 mM 





2.11 Luciferase assay 
Luciferase assay system from Promega was used to measure the enzyme activity. In 
brief, cells were lysed using the passive lysis buffer (PLB) provided by the 
manufacturer. 100 L of PLB was used for each well to lyse the cells transfected in a 
24-well plate. Cells with PLB were incubated for 20 min at room temperature with 
gentle shaking. After the lysis procedure, the cell lysates were aliquoted and frozen 
down in liquid nitrogen immediately. The lysates were then store at -80 °C. For the 
luciferase assay, 10 L of sample was transferred into an opaque white 96-well plate 
(Nunc). The Synergy H1 Hybrid Multi-Mode Microplate Reader (BioTek) system was 
used to inject Luciferase Assay Reagent (LARII) automatically and read the 
luminescence. Background signal was determined by blank and water controls for 
each assay and luciferase activity was normalized according to recommendations 





Nucleofection was performed using the AmaxaTM nucleofectorTM systems. Either 100 
L NuleocuvetteTM or 20L NuleocuvetteTM strip was used for the nucleofection. The 
detailed procedure for nucleofection is: 
1. Add the entire supplement to the NucleofectorTM Solution 3. 
2. Start NucleofectorTM System and create experimental parameter file. 
3. Select for the appropriate NucleofectorTM Program. For optimization we used EO-
115 and FO-115 programs for our experiment after consulting Lonza technical 
support. 
4. Prepare cell culture plates by filling appropriate number of wells with desired 
volume of recommended culture media and pre-incubate plates in a humidified 37 °C 
incubator with 5% CO2.  
5. Pre-warm an aliquot of culture medium to 37 °C.  
6. Prepare DNA to be transfected. For experiments using 100 μL nucleocuvetteTM up 
to 1 μg DNA was used, whereas when 20 μL nucleocuvetteTM was used 0.4 μg DNA 
was transfected. 
7. Count an aliquot of the cells and determine cell density  
8. Centrifuge the required number of cells at 200g for 10 min at room temperature. 
Remove supernatant completely.  
9. Resuspend the cell pellet carefully in room temperature NucleofectorTM Solution. 
10. Prepare mastermixes by dividing cell suspension according to number of 
substrates.  
11. Add required amount of substrates to each aliquot (max. 10 % of final sample 
volume).  
12. Transfer mastermixes into the NucleocuvetteTM Vessels.  
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13. Gently tap the NucleocuvetteTM Vessels to make sure the sample covers the 
bottom of the cuvette.  
14. Place NucleocuvetteTM Vessel with closed lid into the retainer of the 
NucleofectorTM X Unit.  
15. Start NucleofectionTM Process by pressing the “Start” on the display of the 
NucleofectorTM Core Unit. 
16. After run completion, carefully remove the NucleocuvetteTM Vessel from the 
retainer.  
17. Resuspend cells with pre-warmed medium. Mix cells by gently pipetting up and 
down two to three times. 
18. Transfer the cells back to the culture media. 




2.13 Flow cytometry 
HepG2 cells transfected with GFP expression vector were trypsinized and 
resuspended in PBS before the flow cytometry. 20,000~50,000 cells were acquired for 
FACS analysis. LSRFortessaTM cell analyzer and FACSDiva software v6.1.3 (BD 
Biosciences) were used for the acquisition of the samples. FlowJo software V7.6.1 
(Tree Star) was used to analyze the data. GFP expression was detected by the GFP 
laser (excitation 488nm, emission 509nm). Live cell population was first gated by the 
FSC and SSC xy plot. GFP positive cells were gated according to the no transfection 
HepG2 cells control. GFP-PE xy plot instead of GFP histogram was used to gate the 
GFP expression in order to eliminate auto-fluorescence.  
2.14 Statistical analysis 
Results were shown as mean ± S.E.M when more than one experiments were 
performed. Unpaired student t-test was used to determine significance when 
comparing two groups. For the comparison of more than two groups of data, one-way 
ANOVA with Newman-Keuls post hoc test was used. Prism 5 Graphpad software was 
used for the statistical analysis. * represents p value <0.05, ** represents p value 




Chapter 3 Results 
A universal TaqMan-based RT-PCR protocol 




Various technologies for RNA detection have been developed, including northern blotting, 
cloning and RT-PCR. Real-time RT-PCR is generally considered to be the most accurate 
among these methods, and is widely used in research (O'Connor and Glynn 2010). Small 
non-coding RNAs, including siRNAs and miRNAs are found to be important in a variety of 
cellular processes. In particular, endogenous miRNAs have been reported to play pivotal 
roles in the pathogenesis of many diseases, including cancer (Ventura and Jacks 2009). These 
small RNAs, however, cannot be efficiently captured by the current technologies for RNA 
detection. Mature siRNA and miRNAs are usually 17~24 nt long, which is too short to 
provide sufficient complementarity for conventional linear RT-PCR methods. Chen et al. 
introduced a TaqMan RT-PCR method specifically for small RNA detection (Chen, Ridzon et 
al. 2005). This method used a stem-loop RT primer to capture the 3’ end of the targeted small 
RNA and binding was stabilized by base stacking reducing the length of the complementary 
primer binding site. High sensitivity and specificity were observed for this method, which 
was attributed to the stem-loop structure of the RT primer. According to the original design, a 
specific 3’ stem-loop primer and linear forward primer, and one TaqMan probe are needed for 
the detection of each particular miRNA. The TaqMan probe was designed to span the 
junction of the stem-loop primer and target amplicon. Such a design raises the cost for the 
detection and renders the method highly expensive for high-throughput applications. 
In this study we explored the use of db vectors for small RNA expression, therefore we need 
a sensitive, specific and cost-effective method to quantify the small RNAs expressed from 
different vectors. We hypothesized that in the existing detection strategy it was the stem-loop 
RT primer rather than the TaqMan probe that triggered target specificity, and therefore one 
TaqMan probe that was completely complementary to the conserved stem-
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loop primer region of the cDNA should work equally well. With this modified design, we can 
use a single universal TaqMan probe to detect multiple targets. Since the hydrolysis probe is 
the most expensive reagent in this method, such a modification significantly reduces costs, 
making extensive applications feasible. In this study, we have compared the sensitivity and 
specificity of this modified protocol with that of the conventional method.  
The specificity of RNA 3’ ends was also investigated. Our data confirmed that both protocols 
are equally sensitive and specific. 
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3.2 Detection strategy and experimental parameter optimization 
In our modified method, we used a stem-loop primer for the first strand cDNA synthesis and 
a linear primer for second strand synthesis, similar to the standard protocol. The linear 
forward primers were designed to have melting temperatures of 58℃-60℃, using the Primer 
Express 3.0 software (Applied Biosystems). Additional random sequences were added to the 
5’ end to increase the melting temperature if necessary. An overlap with the target’s 3’ end 
was avoided because this could lead to forward primer and stem-loop RT primer binding and 
trigger a false positive signal in the real-time PCR step. The two methods are different in 
terms of the PCR amplicon detection (Figure 8).  
 
Figure 8. Schematic diagram depicting the principle of stem–loop primer-based small 
RNA detection.  
The original design requires one TaqMan probe for each target RNA (lower left). The 
universal design uses a universal TaqMan-based probe which does not overlap with the target 
binding domain of the stem–loop primer and, hence, can be used to detect any target 
sequence (lower right). 
 
Before comparing the two methods, we first optimized the synthesis steps to maximize the 
effective range of the assay. The effects of the following parameters were investigated: 
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1) the length of the target binding domain of the RT primer 
2) the nature of the template 
To investigate the effect of the length of the RT primer binding domain on sensitivity, we 
designed four stem-loop primers with 5-, 6-, 8-, and 11-nt complementarity to the 3’ end of 
the antisense strand of the GFP22 siRNA. Our data demonstrated that the length of the 
binding site significantly affected the sensitivity of the method. Stem-loop primers with 5- or 
6-nt gave us the highest sensitivity. The detection limit for both primers was 103 template 
molecules while primers with 8- or 11-nt overhang had a much higher detection limit (Figure 
9A). 
Next we investigated the effect of the template nature on the robustness of the assay. The 
detection template we used was GFP22 siRNA, which was double-stranded, and the antisense 
strand was the target. To test whether the internal base paring within the template would 
affect the binding of the stem-loop RT primer, we performed reverse transcription with 
siRNA template that was either denatured or not. Real-time quantitative PCR data showed 
that both double-stranded and single-stranded targets were detectable with equal sensitivity, 
indicating that duplex structure of the siRNA template did not interfere with the binding of 




Figure 9. Impact of length of target binding overhang and strand accessibility on the 
sensitivity of the modified protocol.  
The target used is the antisense strand of the GFP22 siRNA duplex. (A) Amplification using 
stem–loop primers with different lengths of the target binding overhang. (B) Detection of 
single-stranded vs. double-stranded target RNA using the stem–loop primer with a 6-nt target 





3.3 Conventional and the universal method are equally sensitive, though to a lower 
extent than originally reported 
After the optimization of the assay, we proceeded to compare the sensitivity of the two 
methods. A TaqMan probe, which binds completely to the conserved sequence of the stem-
loop primer region, was designed. This probe can be used to detect any small RNA of 
interest. In the description of the original method it was reported that this protocol could 
detect as few as seven copies of the lin-4 miRNA (Chen, Ridzon et al. 2005). We ordered one 
custom kit for the siRNA GFP 22 from Applied Biosystems (ABI) who commercialized the 
original method, in order to exclude any errors in the reverse engineering and to consider all 
the intricacies of the original design. Two different batches of siRNA were used to control the 
quality of the template. Our data suggested that both methods could detect the target siRNA 
with the same sensitivity. However, we observed high background signals (see the NTC 
groups) with the commercial kit but not with the modified method.  
To further validate our results, some other templates were tested in addition. Two miRNAs, 
hsa-miR-133b and hsa-miR-146a were chosen as the targets. Mature single-stranded miRNA 
(Dharmacon) and double-stranded miRNA mimics (Ambion) were used as the templates. 
Two commercial kits for these miRNAs (Applied Biosystems) designed based upon the 
original method were used to compare with our modified protocol. The data from these 
miRNA detections further supported the conclusion we got with the siRNA experiment. Both 
methods gauged these miRNAs with equal sensitivity of 103~104 molecules. The sensitivity 
we observed, for both the commercial kits and our design, however, was significantly lower 
than originally reported. Similar results were also obtained from another group (Mantei, Rutz 
et al. 2008). We could not achieve the reported sensitivity even when varying the length of 




Figure 10. Comparison of the sensitivity of conventional probe (Com) and the universal 
probe (Mod) using various templates.  
(A) Detection of the GFP22 siRNA antisense strand derived from two double-stranded 
siRNA batches using both protocols; mean of duplicates with standard deviation. Detection of 
mature miR-133b as part of a double-stranded miRNA mimic (B) or as RNA single-strand 
(C). Detection of mature miR-146a as part of a double-stranded miRNA mimic (D) or as 
RNA single-strand (E). Error bars represent standard errors of the mean of two independent 
experiments, each performed in duplicate. (NTC) No template control; (NEC) no reverse 




3.4 Universal and specific protocols exhibit equal specificity for small RNA detection 
Next we went on to investigate the specificity of the two methods. We evaluated the ability of 
the two methods to discriminate target miRNAs from their corresponding precursors, as well 
as from other mature miRNAs. Originally, stem-loop primer-based RT-PCR protocol was 
claimed to efficiently discriminate target miRNAs from the precursors. When RT primer 
designed for the mature miRNA was used to reverse transcribe the precursor, Ct values 
produced from the qPCR reaction were at least 11 cycles higher than when the correct mature 
miRNA was used as the template (Chen, Ridzon et al. 2005). Here we investigated how 
accurately the modified universal method can discriminate mature miRNAs from their 
precursors, which lack the correct 3’ end that the RT primer would recognize. Precursor 
RNAs of miR-133b and miR-146a were produced by in vitro transcription using PCR 
fragments as the templates as described in the methods section. RNA was purified by TRIzol 
reagent and was loaded on 10% PAGE gel (Figure 11). Ethidium Bromide staining showed 
one band after RNA denaturation, suggesting we got uniform transcription products.  
 
Figure 11. Quality check of in vitro transcribed miRNA precursors.  
(D) denatured; (ND) non-denatured. 
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Then we did serial dilutions of both the mature miRNAs and the precursors and used stem-
loop RT primers designed for the mature miRNAs to perform the reverse transcription. 
Quantitative PCR was done using both commercial kits (specific probe) and our universal 
probe. As shown in Figure 12, both methods can efficiently discriminate the mature miRNAs 
from the precursors. For the highest molecular concentration we tested, i.e. 109 
molecules/reaction, a 7-12 or 9-11 cycle difference was observed with the commercial kits or 
universal protocol, respectively. The data suggest that when the mature miRNA, which is the 
target, are presented with its precursor at equal concentration, in our case 109 molecules, the 
latter will contribute ~1 to 0.1% to the overall signal.  
 
Figure 12. Comparison of the specificity of the conventional probe (Com) and the 
universal probe (Mod) using serially diluted single-stranded mature miRNAs and the 
corresponding miRNA precursors.  
Detection of miR-133b sequences using the conventional probe (A) or the universal probe 
(C). Detection of miR-146a sequences using the conventional probe (B) or the universal 
probe (D). Error bars represent standard errors of the mean of one experiment performed in 
duplicate. (NTC) No template control. 
 
Besides miRNA precursors, we also investigated the discrimination from other mature 
miRNAs for both methods. To do this, we performed a crossover experiment in which we 
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used stem-loop RT primer designed for miR-133b to reverse transcribe miR-146a and vice 
versa. The sensitivity was evaluated using 109 template/nontemplate molecules per reaction. 
We observed a 13-14 cycle difference using both methods, suggesting that both methods can 
discriminate between the correct template and a false-template control sequence. Table 8 
shows the actual Ct values we got from this experiment. Although efficient discrimination 
between different mature miRNAs was observed, it should be noted that we still detected a 
clear signal with the false-template controls and the signal was significantly higher than the 
non-template controls. These results indicate that for the detection with low-abundant 
miRNA species using this method, the results might be compromised by false-positive signal 
contributed by highly abundant miRNAs. In conclusion, our data demonstrated that both 
methods are equally specific in discriminating between small RNA targets and other non-
target counterparts. 
 ss-miR-133b ss-miR-146a 
miR-133b-RT conventional 13.2±0.18 26.7±0.58 
miR-146a-RT conventional 25.5±0.49 12.5±0.35 
miR-133b-RT universal 12.0±0.74 25.6±0.34 
miR-146a-RT universal 26.0±0.74 12.7±0.46 
 
Table 10. Specificity of the conventional and universal probe monitored by cross-
targeting of 10
9




3.5 The universal probe detects eukaryotic endogenous as well as artificially delivered 
small RNAs 
Next we went on to evaluate the performance of the universal stem-loop RT-PCR protocol by 
detecting small RNAs derived from eukaryotic cells. Hsa-miR-133b and hsa-miR-146a were 
selected as the targets. Total RNA was extracted from human adherent fibroblastic HEK293T, 
as well as from T lymphocyte leukemia Jurkat, cell lines. Conventional stem-loop RT-PCR 
protocol was used at the same time for comparison. Figure 13 shows that both methods were 
equally sensitive in detecting the endogenous miRNAs. 
 
Figure 13. Detection of endogenous small noncoding RNAs in eukaryotes with the 
universal probe.  
Detection of endogenous miR-133b (A) and miR-146a (B) using the universal design (Com) 
and universal modified (Mod) protocol in total RNA from human cell lines HEK293T and 




Chapter 4 Results 
Db vectors for small non-coding RNA expression 
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4.1 The concept of minimalized dumbbell-shaped (db) vectors for small RNA expression 
Since its discovery, gene silencing has been a useful tool for biomedical research as well as a 
technique with powerful therapeutic potential. In mammalian systems, gene silencing can be 
achieved by the delivery of artificially designed siRNA duplexes or by endogenous miRNAs. 
For applications in which a strong target gene knockdown is desired, usually a siRNA duplex 
is used for transient silencing. In the cytoplasm, one strand of the siRNA duplex can be 
incorporated into the RISC complex. If a more persistent silencing effect is desirable, shRNA 
will be a better choice. shRNA sequences are usually cloned into plasmids or viral vectors 
and are expressed endogenously after delivery of the vectors. In this case, the vector 
harbouring the shRNA sequence needs to be transcribed in the nucleus. Direct delivery of 
naked plasmid DNA usually results in very low transgene expression in vivo, and recent 
studies indicate this is mainly due to efficient transgene silencing of the expression vector 
(Pule, Savoldo et al. 2008). In addition, unmethylated CpG motifs and bacterial genes such as 
antibiotic selection markers, which can be expressed in eukaryotic cells, are recognized as 
antigens by the immune system (Krieg, Yi et al. 1995). Viral delivery-based expression can 
be an efficient method, however it is also associated with more biosafety concerns such as 
unpredictable insertional mutagenesis, or immune responses triggered by viral proteins.   
Alternative minimalized vectors have been developed to overcome the drawbacks of 
conventional plasmids and viral vectors. Novel vectors like DNA minicircles and dumbbell-
shaped vectors harbor only essential elements needed for mammalian gene expression but are 
devoid of sequences associated with biosafety concerns. Studies in minicircles already 
showed that these vectors could escape vector silencing in vivo and induce much higher 
levels of transgene expression than conventional plasmids (Gracey Maniar, Maniar et al. 
2013).  Similar results have also been reported for dumbbell-shaped vectors (Schakowski, 
Gorschluter et al. 2001, Schakowski, Gorschluter et al. 2007).  
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We improved gene delivery and expression by exploring an advanced dumbbell design that 
either facilitates a further minimization in size, by transcribing small hairpin RNA (shRNA) 
or microRNA (miRNA) precursor structures (i) around one of the dumbbell loops using (ii) a 
minimal H1 promoter with (iii) integrated inverse transcriptional terminator, or alternatively 
employs novel molecular features at the cost of an increase in vector size. Among the latter 
group of features we tested miRNA stems reported to improve shRNA processing and simian 
virus 40 (SV40)-derived enhancer elements described to promote transcriptional activation 
and/or nuclear DNA import. Minimised and to a lesser extent conventional shRNA 
expressing dumbbells triggered facilitated kinetics of cellular and nuclear delivery, 
transcription, and target gene knockdown as compared with corresponding plasmids. A 
miRNA stem and SV40 enhancer elements further improved target gene knockdown 
triggered by shRNA or miRNA-expressing minimised dumbbells in HepG2 cells, 
respectively. Our data clearly support the hypothesis that small size represents an important 
advantage of the dumbbell vector system. However, distinct molecular features which at first 
glance seem to conflict with the paradigm of size minimisation were proven to be very useful.   
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4.2 The design of minimalized small RNA expressing dumbbell-shaped vectors 
A total of 14 db vectors were designed and synthesized. While db-iPR-hp-s/as, db-iPR-miR-
hp-s/as, db-iPTR-hp-s/as and db-iPTR-hp-as/s were designed but not tested by Teo and Tan 
previously in our lab, all the other dbs were newly designed and investigated for the first time 
in this study. As shown in Figure 14, the first six dbs express shRNAs targeting the firefly 
luciferase gene, the other eight dbs were designed to express either the natural miRNA miR-
125b-1 or miR-21 antagonists. Detailed information and the corresponding transcripts from 




5’AAA|                       CA  
      AAGAGCUGUUUCUGAGGAGCCUU   \  
      UUCUCGACAAAGACUCCUCGGAG   A  




5’AAA|             A   C                      CA  
      AAUCUUCUCAGUG GCG GGAGCUGUUUCUGAGGAGCCUU   \  
      UUAGAAGAGUCAU CGU UCUCGACAAAGACUCCUCGGAG   A  




5’---------|                      CA 
            GAGCUGUUUCUGAGGAGCCUU   \ 
            CUCGACAAAGACUCCUCGGAG   A 






5’---------|                      CA  
            AGGCUCCUCAGAAACAGCUCUU   \  
            UCCGAGGAGUCUUUGUCGAGAG   A  




5’--|                      CA 
     GAGCUGUUUCUGAGGAGCCUU   \ 
     CUCGACAAAGACUCCUCGGAG   A 




5’--|                      CA 
     GAGCUGUUUCUGAGGAGCCUU   \ 
     CUCGACAAAGACUCCUCGGAG   A 





5’--|U    UC   U   UC  UG   C           AU     CC 
      GCGC  CUC CAG  CC  AGA CCUAACUUGUG  GUUUA  \ 
      CGUG  GAG GUC  GG  UCU GGAUUGGGCAC  UAAAU  G 




5’--|U    UC   U   UC  UG   C           AU     CC 
      GCGC  CUC CAG  CC  AGA CCUAACUUGUG  GUUUA  \ 
      CGUG  GAG GUC  GG  UCU GGAUUGGGCAC  UAAAU  G 






5’--|U    UC   U   UC  UG   C           AU     CC 
      GCGC  CUC CAG  CC  AGA CCUAACUUGUG  GUUUA  \ 
      CGUG  GAG GUC  GG  UCU GGAUUGGGCAC  UAAAU  G 




5’--|U    UC   U   UC  UG   C           AU     CC 
      GCGC  CUC CAG  CC  AGA CCUAACUUGUG  GUUUA  \ 
      CGUG  GAG GUC  GG  UCU GGAUUGGGCAC  UAAAU  G 
3’UUU^    CU   C   GA  GU   C           -C     UU 
 
db-anti-miR-21 (A1, A2, A3, A4) (157/161bp) 
 
Predicted transcript A1 
5’-UGCCAUGAGAUUCAACAGUCAACAUCAGUCUUU-3’ (Unstructured) 
Predicted transcript A2 
           CCA  AGA 
5’-|GGUGUUG   UG   \ 
3’UUCUACAAC   CA   UU   
           -GU  AAC 
Predicted transcript A3 
5’---|AUUCAACA       AU 
              GUCA-AC  C 
              UAGU UG  / 
3’UUGCCCAUCGAA^   C  -A     
Predicted transcript A4 
             CCA  AGA 
5’-|CUGGUGUUG   UG   \ 
3’UUGACUACAAC   AC   UU 
             -UG  AAC 
Figure 14. Schematic illustration of designed db vectors and the predicted transcripts. 
 
Db-iPR-hp-s/as is the basic design for hairpin db, which embodies some common features 
shared by all the variants. The minimal H1 promoter drives the shRNA expression, and 
transcription is terminated by a pentathymidine motif (5T termination signal). We have 
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integrated the restriction sites into the minimal H1 promoter (iPR) for all constructs. The 54nt 
shRNA transcript targets the firefly luciferase gene, and because transcription starts before 
the 5T termination signal, this shRNA has a 3A 5’ overhang. Db-iPR-miR-hp-s/as, db-iPTR-
hp-s/as and db-iPTR-hp-as/s are variations of the basic design. In db-iPR-miR-s/as, we 
incorporated part of the stem of hsa-miRNA-30, which is commonly used for optimizing 
shRNA expression. In this case a miRNA-like molecule is produced and it should be 
processed more efficiently by the endogenous miRNA processing machinery. For both db-
iPR-hp-s/as and db-iPR-miR-hp-s/as, transcription starts with the T5-motif, therefore 
produces 5’ overhangs. Since the 5’ overhang is undesirable and transcription of the 5T 
signal is unnecessary, we further incorporated the 5T sequence into the promoter by replacing 
the last few bases of the promoter (promoter-terminator integration, iPTR). The resulting 
constructs are db-iPTR-hp-s/as and db-iPTR-hp-as/s. We assumed that this would not 
compromise the transcription efficiency because previous studies have demonstrated that the 
last few bases of the H1 promoter were not critical for its activity (Kaykas and Moon 2004, 
Jian, Peng et al. 2006). With this new design, transcription initiation and termination 
functions are fulfilled by an integrated promoter-terminator element. Db-iPTR-hp-s/as and 
db-iPTR-hp-as/s have different shRNA sequence orientations: for db-iPTR-hp-s/as, the 
shRNA cassette contains the order sense-loop-antisense, whereas the reverse order antisense-
loop-sense was used for db-iPTR-hp-as/s. However, because in these two dbs we put the 5T 
terminator before the restriction sites, they generate shRNAs that have 9 nt 3’ overhangs.  
A conventional linear db encoding the shRNA, termed db-iPR-linear-s/as, was also 
constructed as a positive control. For the linear db, the shRNA cassette was designed in the 
order sense-loop-antisense, and was positioned between the mH1 promoter and 5T 
termination signal. The parental plasmid pSuper-shLUC from which we produced the linear 
db, was also used as plasmid control in this study. Both the linear db and its parental plasmid 
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generate shRNA sequences with UU 3’ overhangs. In order to directly compare the novel 
hairpin db with the linear db and the plasmid, we designed db-iPRT-hp-s/as to produce 
exactly the same transcript as the linear db and the plasmid (Figure 15). Such a design allows 
us to use the same amplicon for the universal stem-loop primer-based TaqMan RT-PCR 
protocol, which has been described in the previous section, to detect this transcript and 
evaluate the transcription efficiency of these different vectors. 
Besides artificial shRNAs, we were also interested in expressing natural miRNAs and 
miRNA inhibitors. miRNAs have been reported to play pivotal roles in many cellular or 
pathological processes, including cancer (Lujambio and Lowe 2012). MiRNAs can act as 
either oncogenes (termed oncomir) or tumor suppressor genes depending on their targets in 
certain types of cells. Here we synthesized a DNA template for the hsa-miR-125b-1 gene and 
tried to express this miRNA using a db vector. In parallel, we have also designed four 
antagonists against has-miR-21. We explored the use of dbs to deliver these antagonists into 
human cells. MiR-125b has been reported to be a tumor suppressor gene in liver cancer, by 
targeting oncogenes such as LIN28B and IL6R (Liang, Wong et al. 2010, Jia, Wang et al. 
2012). MiR-21, on the other hand, is shown to be oncogenic in multiple types of cancers, 
including HCC (Wong, Jiang et al. 2013). Previously we also observed that miR-125b was 
significantly down-regulated in tumor tissues from HCC patients, whereas there was strong 
up-regulation of miR-21 in the same cohort of patients. We have constructed both a linear db, 
termed db-linear-miR-125b, and a hairpin db, termed db-hairpin-miR-125b to express miR-
125b. Four linear dbs expressing different antagonist sequences against miR-21 precursor 
were made to test the antagonist function. To evaluate the expression of the miRNA and the 
miRNA antagonist, we constructed a miRNA sensor that harboured fully complementary 
binding sites of the corresponding miRNA.  
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To improve nuclear targeting of the vector, we generated another two miR-125b dbs for 
which either a minimal or a full-length SV40 enhancer was fused upstream of the promoter. 
Modifications were made to the db-hairpin-miR-125b to generate db-mEnh-miR-125b and 
db-fEnh-miR-125b. We wanted to investigate if these sequences can improve the nuclear 
import and/or the transcription of the existing vector. The DNA nuclear targeting sequences 
derived from simian virus 40 (SV40), first described by Dean et al. in 1999, have been 
reported to improve nuclear import in several previous studies (Dean, Dean et al. 1999, Dean, 
Strong et al. 2005, Lam and Dean 2010). Both the 237 bp full-length SV40 enhancer, termed 
fEnh, and a 72 bp minimal version of it, termed mEnh, were reported to enhance nuclear 
import and expression of DNA vectors in various different cell types (Lam and Dean 2010). 
It is speculated that because DTS contain binding sites for a number of transcription factors, 
DTS-containing molecules can piggyback on these transcription factors and make their way 
to the nucleus using the protein import machinery. A schematic illustration of the minimal 
enhancer sequence is shown in Figure 15, predicted transcription factor binding sites are 
highlighted. 
 
Figure 15. Clustering of transcription factor binding sites within the 72 bp minimal 
SV40 enhancer.  




4.3 Minimal H1 promoter is suitable for small RNA expression 
Type III class of RNA Polymerase III promoters such as H1 promoter or U6 promoter are 
often used for small RNA expression. These promoters are ideal for small RNA expression 
because all their elements are located upstream of the transcribed region, and the 
transcription initiation sites are well-defined (Tuschl 2002). Transcription is precisely 
terminated by the 5T termination signal, generating an UU residual as the 3’ end. These 
features make sure that the designed shRNA transcript will be generated, and undesired 
sequences, such as long dsRNA that may come from rolling circle transcription can be 
avoided. It was reported that dsRNA longer than 30bp could induce interferon response in 
mammalian cells (Karpala, Doran et al. 2005). Although the sizes of the U6 and the H1 
promoters are different, conserved sequences and protein-binding sites are actually identical 
(Myslinski, Ame et al. 2001). Previous studies reported that the H1 promoter was more 
flexible than the U6 promoter with regard to sequences that can be transcribed (Tuschl 2002). 
Therefore we chose the H1 promoter for shRNA expression. The full-length H1 promoter is 
227bp in length, but all the four essential promoter elements, namely the Octamer motif, the 
Staf-binding sites, the Proximal Sequence Element and the TATA box are located close to 
each other in a compact region between position -100 and the transcription start site 
(Myslinski, Ame et al. 2001). Maximal transcription efficiency can be achieved as long as 
these four elements are present. With this information in mind, we chose to use a minimal 
version (99bp) of the H1 promoter instead of the full-length version to drive the expression, 
so that the overall size of the db vector can be kept to a minimum.  
In order to make sure that the minimal H1 promoter used in this study is as effective as the 
full-length H1 or other commonly used promoters, we directly compared the activity of the 
minimal H1, full-length H1, and the RNA polymerase II CMV promoters. We first replaced 
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the full-length H1 promoter in the pSuper plasmid with the minimal H1 promoter to create 
the pSUPER-mH1 cloning vector. Then we cloned the pre-miR-125b-1 gene into both pSuper 
and pSuper-mH1. Similarly, we also cloned miR-125b-1 into pCDNA3.1 (-) plasmid 
(Invitrogen), which uses the CMV promoter to drive transgene expression (Figure 16A). The 
cloned sequences were confirmed by DNA sequencing. HEK293T cells were transfected with 
the three plasmids pSuper-125b, pSuper-mH1-125b, and pCDNA3.1-125b. Total RNA was 
isolated 24h post transfection and expression levels of the mature miR-125b were determined 
by our novel stem-loop primer-based TaqMan RT-PCR protocol. Threshold cycles were 
converted into actual copy numbers by comparing with the standard curve we generated 
using synthetic miRNA mimic (Ambion). Expression levels from different expression vectors 
are shown in Figure 16B. In HEK293T cells, miR-125b-1 expression levels from pSuper-
mH1-125b are comparable to those from pSuper-125b and pCDNA-3.1-125b, suggesting the 
minimal H1 promoter is at least as powerful as the full-length H1 promoter or the CMV 
promoter. 
We also compared the knockdown efficiencies triggered by these three vectors using the 
miR-125b sensor construct in HEK293T cells. In this experiment, the sensor, which harbors 
three miR-125b binding sites, was co-transfected with the miR-125b expression vectors. The 
reporter vector without miRNA binding site (pMIR) and the empty vectors without miRNA 
sequence were used as negative controls. Luciferase expression was determined 48h post 
transfection. As shown in Figure 16C, we only observed significant knockdown when sensor 
was co-transfected with the miRNA expression vector. Knockdown efficiencies triggered by 
the three vectors were comparable. In summary, our data demonstrate the mH1 promoter is as 





Figure 16. Comparison of promoter strengths with regard to miR-125b expression.  
A, The miR-125b expression cassette was cloned into plasmid vectors pCDNA3.1 (CMV 
promoter), pSuper (H1 promoter) and a modified pSuper (mH1 promoter). B, 5X10
5
 cells 
seeded in 6-well were transfected with 1000ng miR-125b expressing vectors or the respective 
empty control vectors. 24h post transfection small RNA was isolated and absolute miR-125b 
levels were quantified using TaqMan-probe-based rtRT-PCR. C, 5X10
4
 cells seeded in 24-
well were transfected with 100ng 125b-Sensor luciferase reporter, which harbours three fully 
complementary miR-125b binding sites, or sensor-negative parental pMIR vector, together 
with 300 ng miR-125b expressing vectors or the respective empty control vectors. Luciferase 
activity was measured 48h post transfection.   
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4.4 Optimization of the production of small RNA expressing hairpin dbs 
Two strategies for the production of dumbbell-shaped DNA vectors were reported. Firstly, 
the enzymatic ligation assisted by nucleases (ELAN) method (Cost 2007) is based on the 
ligation of terminal loop-forming oligos to the linear double-stranded expression cassette, the 
latter of which can be generated by hybridization of chemically synthesized complementary 
oligos or alternatively be derived from endonuclease cleavage of plasmid DNA or PCR 
products. Thereby the frequent formation of misligated products is suppressed by restriction 
endonucleases which cleave off-pathway products but which do not affect properly-ligated 
dumbbells. The disadvantage of this method relies in low overall yields of dumbbell 
formation (<50%). The second strategy is a PCR-based nicking enzyme-dependent method 
(Taki, Kato et al. 2004). This method is based on PCR amplification of the sequence of 
interest using primers introducing terminal cleavage sites for the nicking enzyme Nb.Bpu10l. 
This enzyme is being used to nick the termini of the PCR product, followed by removal of 
the terminal oligos, refolding of the generated single-stranded overhangs, and subsequent 
ligation of the loops. The reported overall yields of this method are with >90% (94%) higher 
than for method 1. 
As described in Chapter 2, we have developed a new strategy for the synthesis of small RNA 
expressing hairpin dbs that combines features of both conventional methods. In brief, the 
minimal H1 promoter is digested with one nicking enzyme and one conventional restriction 
enzyme and after digestion at 5’ end the loop structure forms, while the 3’ end is ligated to a 
hairpin DNA template coding the small RNA sequence. We first tested if this strategy could 
successfully generate the desired db. As can be seen in Figure 17A, agarose gel 
electrophoresis showed that only one band with the expected size was detectable after the 
exonuclease treatment, suggesting the db could be synthesized using this strategy. However, 
we also noticed that the conversion yield was not very high, when we compared the band 
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intensity between the educts before and the product after exonuclease treatment. The data 
indicated that a substantial fraction of the vector was not ligated properly and was destroyed 
during the exonuclease digestion. We reasoned that there might be two possible factors that 
affect the ligation, (i) after nicking enzyme digestion, the antisense strand which was cleaved 
might still bind to the sense strand and could inhibit the loop formation at the 5’ end, and (ii) 
ligation might be compromised by digested small DNA fragments and the buffer from the 
digestion reaction. We therefore designed an oligonucleotide that was completely 
complementary to the cleaved strand, which we termed neutralizing oligo. By addition of this 
neutralizing oligo and additional column purification, which removes the small oligos and 
salt from digestion reaction, before the ligation step, we hypothesized the conversion yield 
could be increased. As shown in Figure 17B, four different batches of dbs were produced 
including or not including the additional treatments. The conversion yield was higher when 
column purification was performed, whereas the neutralizing oligo did not have much effect. 
With the addition of the column purification step we could achieve up to 90% conversion and 




Figure 17. Optimization of db production.  
A. Gel electrophoresis of db products post ligation step (Exo-) and exonuclease treatment 
(Exo+) step. B. Additional treatments increased db conversion yield. Original method (1), 
original method with neutralizing oligo (2), original method with column purification (3), and 
original method with both treatments (4) were tested. The highest conversion yield (91%) 
was achieved with the addition of column purification step. The conversion yield is defined 





4.5 Dumbbells can be efficiently transfected into tissue culture cells by lipofection 
Next we studied the transfection efficiencies of db vectors. Lipofection was optimized for the 
transfection of plasmid DNA or siRNA and is widely used in most laboratories. However, 
since the structure of a db vector is very different from that of a plasmid, we investigated 
whether commercially available transfection reagents could efficiently deliver dbs into tissue 
culture cells. We first compared equimass transfection of the shRNA expression plasmid 
pSuper-shLUC and a corresponding linear db vector db-iPR-linear-s/as. To detect the vectors, 
we designed primers and a TaqMan probe that specifically bind to a region within the 
minimal H1 promoter. Because the promoter sequence is shared by the plasmid and all the 
small-RNA expressing dbs, this strategy can be used to determine the abundance of any 
target vector. HEK293T cells were transfected with 1g plasmid and linear db using two 
different transfection reagents, Lipofectamine 2000 (Invitrogen) and TurboFect (Thermo 
Scientific). Episomal vector DNA was isolated using TRIzol reagent 24h post transfection. Ct 
values were converted to actual copy numbers by comparison with standard curves generated 
with the plasmid or db, respectively. As shown in Figure 18, we detected much stronger 
signals in the db groups for both transfection reagents tested. 25- to 40-fold more dbs were 
detected. This was expected because we did an equimass comparison and since db is much 




Figure 18. Comparison of db and plasmid transfection efficiencies. 
5x10
5
 HEK293T cells seeded in 6-well were transfected with 1000ng pSuper-mH1-125b or 
linear-125b db. Cells transfected with no DNA served as the mock. Episomal DNA was 
isolated 24h post transfection. Vector copy numbers were quantified using rtPCR. Error bars 
represent standard errors of the mean of technical duplicates from one experiment. 
 
Next we studied the kinetics of the transfection. HepG2 cells were transfected with equimolar 
amounts (1 pmol) of plasmid, linear db db-iPR-linear-s/as and hairpin db db-iPRT-hp-s/as 
using Lipofectamine 2000. Because the dbs were much smaller than the plasmid, an 
equimolar amount of the db corresponds to much less DNA as compared with the plasmid. In 
order to keep the amount of Lipofectamine 2000 constant, we used pVAX1 as feeder DNA. 
Episomal DNA vectors were isolated 10min, 1h, 6h, and 24h post transfection. Vector copy 
numbers were determined using the same real-time PCR strategy as described above. Ct 
values were converted to actual copy numbers using standard curves generated by the 
corresponding vector, because plasmid and dbs exhibit different PCR amplification 
efficiencies. As shown in Figure 19A, the linear db delivery was facilitated up to 4.4- to 6.2-
fold (p<0.05) as compared with the plasmid. No significant difference regarding the delivery 
was detected between plasmid and the hairpin db. Our data suggest transfection of linear db 
is more efficient than plasmid and hairpin db. We do not have a plausible explanation for the 
difference observed between the linear and the hairpin db, as the structure of the dbs is 
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identical and the size of the hairpin db is even smaller. As the next step, the transfection 
experiment was repeated in HepG2 cells and vector copy numbers were determined using 
SybrGreen-based rtPCR quantification. Using SybrGreen-based quantification, facilitated 
delivery was observed for both dbs as compared with the plasmid. No significant difference 
in terms of cellular delivery was detected between the linear and hairpin db (Figure 20). 
These data indicate that the observed difference in terms of cellular delivery as shown in 
Figure 19 was rather an artefact associated with the TaqMan-probe-based PCR detection. 
Taken together, our data demonstrate that db vectors can be transfected into tissue culture 
cells, to a similar extent as or better than conventional plasmid, by lipofection.  
 
Figure 19. Kinetics of cellular db and plasmid delivery into tissue culture cells detected 
using TaqMan rtPCR.  
A. 5x10
5 
HepG2 cells seeded in 6-well were transfected using Lipofectamine 2000 with 
equimolar amounts (1 pmol/well) of either a db-vector (two different designs) or a plasmid 
expressing a luciferase targeting shRNA. 10min, 1h, 6h, and 24h post transfection total 
episomal DNA was isolated and vector copy numbers were quantified by TaqMan-probe-
based rtPCR.  B. Compiled kinetics of cellular delivery. Error bars represent standard errors 





Figure 20. Kinetics of cellular db and plasmid delivery into tissue culture cells detected 
using SybrGreen rtPCR. 
A. 5x10
5
 HepG2 cells seeded in 6-well were transfected using Lipofectamine 2000 with 
equimolar amounts (1 pmol/well) of either a db-vector (two different designs) or a plasmid 
expressing a luciferase targeting shRNA. 10min, 1h, 6h, and 24h post transfection total 
episomal DNA was isolated and vector copy numbers were quantified by SybrGreen-based 
rtPCR.  B. Compiled kinetics of cellular delivery. Error bars represent standard errors of the 




4.6 Nuclear import is more efficient for dumbbell vectors 
Our small-RNA expression db vectors are less than 200 bp in length, whereas the size of the 
plasmid counterpart is above 3 kbp. Despite their supercoiled conformation, previous studies 
have shown that nuclear diffusion is the limiting step for ectopic plasmid transgene 
expression (Kay 2011). Since dbs are much smaller, we speculated that these vectors might 
pass the nuclear membrane more efficiently. To test this hypothesis, we performed 
transfection as indicated in the transfection experiment in section 4.5, and extracted the nuclei 
at various time points post transfection. We then isolated the nuclear episomal DNA by 
TRIzol extraction and measured the abundance of the transfected vectors by rtPCR 
quantification of the minimal H1 promoter. The kinetics of nuclear vector import are shown 
in Figure 21. 
 
Figure 21. Kinetics of the nuclear import of plasmid and dbs.  
A. 5x10
5 
HepG2 cells seeded in 6-well were transfected using Lipofectamine 2000 with 
equimolar amounts (1 pmol/well) of either a db-vector (two different designs) or a plasmid 
expressing a luciferase targeting shRNA. 10min, 1h, 6h, and 24h post transfection nuclear 
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episomal DNA was isolated and vector copy numbers were quantified by TaqMan-probe-
based rtPCR.  B. Compiled kinetics of nuclear delivery. Error bars represent standard errors 
of the mean of three independent experiments each performed in duplicates. 
As expected, we detected significantly stronger signals for the dbs at all time points post 
transfection, suggesting more db vectors entered the nuclei during the investigated period of 
time. Nuclear db delivery was facilitated up to 74 or 25-fold 10min or 24 hours post 
transfection (p<0.001). Surprisingly, the nuclear diffusion seemed to be a very fast process 
for the small vectors, as we could detect the dbs as early as 10min post transfection. At that 
time point the plasmid could not be detected yet. In summary, we demonstrated that db vector 
can be more efficiently imported into the nucleus, and this was probably responsible for the 




4.7 Dumbbells induce higher levels of small RNA expression and hairpin-template 
transcription is at least as efficient as linear transcription 
We next studied the kinetics of transgene expression using a similar experimental design as 
shown in the transfection experiment. According to our new db design, the transcriptional 
template DNA exhibits a stem-loop configuration. We investigated whether this DNA 
template can be correctly and efficiently transcribed. As discussed in the previous section, the 
plasmid vector, a linear db, and a hairpin db were designed to generate identical RNA 
transcripts. We therefore used the universal stem-loop primer-based RT-PCR protocol to 
specifically capture this shRNA transcript. For the hairpin db, we hypothesized that the 
transcription could go around the hairpin DNA template. This is a novel design and has not 
been tested. We were also interested to investigate if this novel design of a transcription 
cassette was functional. HepG2 cells were transfected with equimolar amounts (1 pmol) of 
DNA and RNA samples were collected 10min, 1h, 6h, and 24h post transfection.  The 




Figure 22. Kinetics of the transcription of plasmid and dbs.  
A. 5x10
5 
HepG2 cells seeded in 6-well were transfected using Lipofectamine 2000 with 
equimolar amounts (1 pmol/well) of either a db-vector (two different designs) or a plasmid 
expressing a luciferase targeting shRNA. 10min, 1h, 6h, and 24h post transfection total RNA 
was isolated and shRNA transcripts were quantified by the universal TaqMan-probe-based 
rtRT-PCR protocol as discussed in Chapter 3. Data were normalized to the expression levels 
of -actin. Transfection of empty vector pVAX1 served as the control. B. Compiled kinetics 
of transcription. Error bars represent standard errors of the mean of three independent 
experiments each performed in duplicates. 
 
As shown in Figure 22, at all investigated time points, the kinetics indicate a clear advantage 
of the dumbbells over the corresponding plasmid in terms of shRNA transcription. Db-
triggered shRNA transcription was enhanced 12 to 7-fold (p<0.001) 10 min or 24 hours post 
transfection. This is in agreement with previous studies on minicircles and dbs which showed 
transcriptional advantages for alternative minimised DNA vectors. Moreover, no significant 
difference in terms of transgene expression was detected between linear and hairpin dbs, 
suggesting our novel design could produce the expected transcript, and that hairpin-template 
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transcription was at least as efficient as transcription of the conventional linear design. In fact, 
we observed significantly higher expression for the hairpin db at 10 min post transfection, 
indicating the onset of transcription was probably faster for the hairpin vector.  
109 
 
4.8 Kinetics of target gene knockdown 
In the next step we investigated the kinetics of target gene knockdown triggered by the db 
vectors or the corresponding plasmid. HepG2 cells were co-transfected with the luciferase 
expression construct CMV-pGL3-control (250ng) and equimolar amounts (0.12 pmol) of 
plasmid, linear db, or hairpin db. Initially we tried to investigate the same time points as in 
the other kinetics experiments. However, luciferase gene expression was not yet detectable at 
10min and 1h post transfection. We therefore collected samples at 6h, 12 h, 24 h post 
transfection. As shown in Figure 23, significant target gene knockdown could be detected as 
early as 6 hours post transfection for all three shRNA expression constructs. 
 
Figure 23. Kinetics of shRNA-triggered target gene knockdown.  
A. 5x10
4
 HepG2 cells seeded in 24-wells were co-transfected using Lipofectamine 2000 with 
a luciferase reporter vector (250 ng/well) and equimolar amounts (0.12 pmol/well) of either a 
db-vector (two different designs) or a plasmid expressing a luciferase targeting shRNA. 6h, 
12h, and 24h post transfection shRNA-triggered luciferase knock-down was measured. 
Luciferase expression was not yet detectable 10min and 1h post transfection. B. Compiled 
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kinetics of target gene knockdown. Error bars represent standard errors of the mean of three 
independent experiments. 
 
In agreement with the data we got from the transcription experiment, db vector-triggered 
target gene knockdown was significantly stronger as compared with the plasmid at 6 hours or 
12 hours post transfection. At 24 hours post transfection, significant difference in terms of 
target gene knockdown was only observed between the plasmid and the hairpin db. No 
significant difference was observed between the linear and the hairpin dbs for all time points. 
This is in agreement with the transcriptional data of the previous experiment, as no 
significant difference in terms of transcription between the two dbs was observed at 6h or 
later. Taken together, these data demonstrate that db vectors are more potent than plasmids in 




4.9 Effects of a miRNA-stem, strand orientation, and promoter-terminator 
amalgamation on target gene knockdown 
Next we investigated the effects triggered by new molecular features including a miRNA-
stem, a change in the strand orientation, and integration of an inverted transcriptional 
terminator into the mH1 promoter (iPTR) on shRNA-triggered target gene knockdown 
efficiency. HEK293T and HepG2 cells were transfected with db constructs db-iPR-hp-s/as, 
db-iPR-miR-hp-s/as, db-iPTR-hp-s/as, and db-iPTR-hp-as/s together with the luciferase 
vector pGL3-control. Equimolar amounts of the four dbs were used and the luciferase assay 
was performed 48h post transfection. As shown in Figure 24, we observed significant target 
gene knockdown triggered by all four db vectors. Compared with db-iPR-hp-s/as, db-iPR-
miR-hp-s/as exhibited 1.3 to 1.5-fold stronger knockdown (p<0.05) of luciferase gene 
expression in HEK293T and HepG2 cells, respectively, indicating the miR-30-stem enhanced 
the target gene knockdown efficiency. For db-iPTR-hp-s/as, we used the same hairpin DNA 
template sequence as for db-iPR-hp-s/as, but the inverted 5T termination signal was 
integrated into the promoter sequence. This design further shortened the overall length of the 
vector and simplified the production procedure. This modification did not compromise the 
knockdown efficiency of the construct. As compared with db-iPR-hp-s/as, db-iPTR-hp-s/as 
triggered either stronger or comparable target gene knockdown, depending on the cell lines 
used. For db-iPTR-hp-s/as and db-iPTR-hp-as/s, we swapped the strand orientation in order 
to study the effect of strand bias. Changing the sense-loop-antisense orientation of the 
shRNA to the antisense-loop-sense orientation improved the silencing activity of the resulting 





Figure 24. Knock-down of firefly luciferase expression triggered by different anti-
luciferase shRNA-expressing minimised dumbbells.  
A, Structures of hairpin (hp) template-transcribing dumbbells (db) containing the minimal H1 
promoter (mH1), an inverted transcriptional terminator (A5) which for some constructs is 
integrated into the mH1 promoter forming an integrated promoter-terminator element (iPTR), 
and a hairpin-structured shRNA transcription template in sense-loop-antisense (s/as) or 
antisense-loop-sense (as/s) orientation. The hairpin template of construct db-miR-hp-s/as 
harbours a hsa-miR-30 stem (miR) extension. 5x10
4
 HEK293T cells (B) or HepG2 cells (C) 
were co-transfected in 24-wells with 400 ng pGL3-control luciferase reporter and 100 ng 
dumbbell DNA and luciferase knock-down was monitored 48h post transfection. Error bars 
indicate mean deviations from average of three to five independent experiments.  
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4.10 Dumbbell vector drives miRNA expression  
Besides artificial shRNAs, we were also interested in expressing natural miRNAs by the db 
vector system. Db-driven miRNA expression has not been reported yet, though miRNAs are 
involved in many important physiological and pathological processes, and therefore these 
small RNA molecules hold great therapeutic potential. For our studies we selected miR-125b-
1. MiR-125b has been reported to be down-regulated in many types of cancers, including 
colorectal cancer, breast cancer, gastric cancer, non-small cell lung cancer (NSCLC) and 
glioblastomas (Banzhaf-Strathmann and Edbauer 2014). We have also observed down-
regulation of this miRNA in Hepatocellular Carcinoma (HCC) patients (Jiang et al. 
unpublished data). Using a similar design as described above, we synthesized the miR-125b-
expressing dumbbells db-linear-miR-125b and db-hairpin-miR-125b, with a linear or hairpin-
template miR-125b transcription cassette.  
In order to monitor the expression of miR-125b, we generated the 125b-Sensor construct 
using the pMIR-Report (Promega) as the parental vector. The structure of 125b-Sensor is 
shown in Figure 25A. Three fully complementary tandem miR-125b binding sites were fused 
to form the 3’ UTR of the luciferase gene. The functionality of the sensor plasmid was tested 
by transfection of HepG2 cells with the sensor plasmid alone and compared with co-
transfection of sensor plasmid plus feeder DNA or the miR-125b-expressing plasmid. 24h 
post transfection luciferase expression was measured and standardised relative to the 
expression of the sensor-negative reporter vector (Figure 25B). The sensor vector efficiently 
detected endogenous miR-125b expression as well as plasmid-triggered miR-125b 
overexpression. 
Next HepG2 cells were co-transfected with the sensor plasmid and the different miR-125b-
expressing vectors. Due to the large difference in molecular weight between the plasmid 
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vector and the dumbbells, it is difficult to compare equimolar amounts with comparable 
transfection efficiencies. Therefore we compared equimass amounts of the miR-125b 
expressing vectors in this experiment using identical amounts of lipofectamin 2000. Under 
these experimental conditions, the dumbbell vectors and most pronounced the minimised 
dumbbells triggered 3.9-fold (p<0.01) stronger target gene knockdown as compared with the 
plasmid vector (Figure 25C). No difference in knockdown activity was detected for 
dumbbells produced with the new protocol or the ELAN method indicating both protocols 
produce functionally equivalent minimised dumbbells. The functionality of the minimised 




Figure 25. Knock-down of firefly luciferase-miR-125b sensor reporter gene expression 
triggered by hsa-miR-125b-expressing dumbbells. 
A, Design of the miR-125b sensor plasmid pMIR-125b-Sensor harbouring three miR-125b 
binding site in the 3’ UTR, the plasmid pMIR-125b and the dumbbell db-linear-miR-125b 
both harbouring a linear miR-125b expression cassette, and the minimised dumbbell db-
hairpin-miR-125b equipped with a hairpin miR-125b transcription template. Sequences 
coding for mature miR-125b (red) and miR-125b* (blue) are highlighted. B, Sensing of 
endogenous and/or pMIR-125b-triggered miR-125b overexpression. 5x10
4
 HepG2 cells 
seeded in 24-wells were (co-)transfected with 400 ng pMIR or pMIR-125b-Sensor plus 100 
ng pSuper feeder DNA or 100 ng pMIR-125b. C, Sensing of plasmid vs. dumbbell-driven 
miR-125b overexpression in HepG2 cells. 5x10
4
 HepG2 cells were transfected in 24-wells 
with 250 ng sensor plasmid alone or together (+) with 250 ng miR-125b expressing 
dumbbells or plasmid. Dumbbell db-hairpin-miR-125b was generated either using the 
conventional method (ELAN) or our (New) protocol. 5x10
4 
HEK293T (D) or CL48 (E) cells 
seeded in 24-wells were (co-)transfected either with 400 ng pMIR-125b-Sensor alone or 
together with 100 ng db-hairpin-miR-125b (New). (B) to (D), Luciferase knockdown was 
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monitored 48h post transfection. Error bars indicate mean deviations from average of three to 




4.11 SV40 enhancer elements significantly improve target gene knockdown triggered by 
minimised miRNA-expressing dumbbells 
Accelerated passive diffusion from the cytoplasm into the nucleus is regarded to be one of the 
key features that can be assigned to dumbbell vectors. For larger plasmid DNA it was 
reported that certain sequences harbouring transcription factor binding sites significantly 
enhance gene expression. Examples are the SV40 enhancer sequence (Dean, Dean et al. 
1999), the smooth muscle -actin (SMGA) promoter (Miller and Dean 2008), and the origin 
of replication of the Epstein-Barr virus (oriP), the latter of which depends on the expression 
of the viral nuclear antigen 1 (EBNA1) in order to be functional (Langle-Rouault, Patzel et al. 
1998). Both, transcriptional activation as well as active nuclear DNA import and retention 
can account for the enhancement of gene expression triggered by these sequence elements. 
We investigated whether this strategy is suitable to further facilitate nuclear import and gene 
expression of dumbbell vectors. Therefore we implemented either the 237 bp full-length 
SV40 enhancer (fEnh) or a 72 bp minimal version (mEnh) of it into the minimised miR-
125b-expressing dumbbell upstream of the mH1 promoter (Figure 26A) to generate 
dumbbells db-fEnh-miR-125b and db-mEnh-miR-125b. In HepG2 cells co-transfected with 
the pMIR-125b sensor plasmid and the dumbbell vectors, strongest miR-125b-mediated 
luciferase knockdown (93%; p<0.001) relative to the control was triggered by the dumbbell 
harbouring the full-length SV40 enhancer, followed by the dumbbell with the minimal SV40 
enhancer (87%; p<0.001), and the enhancer-negative parental dumbbell vector (69%; 
p<0.001) (Figure 26B). These data demonstrate, SV40 enhancer elements can significantly 
enhance dumbbell-driven miRNA expression, though their implementation triggers a 
relatively stronger increase of vector size in case of the small dumbbells (47 to 156%) 




Figure 26. SV40 enhancer sequences improve dumbbell-driven hsa-miR-125b-triggered 
target gene knockdown.  
A, Design of hairpin template miR-125b-expressing dumbbell vectors. db-hairpin-miR-125b: 
parental dumbbell lacking an enhancer; db-mEnh-miR-125b: dumbbell harbouring the 72 bp 
minimal SV40 enhancer; db-fEnh-miR-125b: dumbbell including the 237 bp full length 
SV40 enhancer. B, Knockdown of luciferase-miR-125b sensor reporter gene expression by 
miR-125b over-expressed from different dumbbells in HepG2 cells. 5x10
4
 cells seeded in 24-
wells were (co-)transfected with 100 ng pMIR-125b-Sensor alone or together with 1.5 pmol 
dumbbell DNA (pUC119 plasmid was used as the feeder DNA) and luciferase knockdown 
was monitored 48h post transfection. Error bars indicate standard errors of the mean of four 
independent experiments.  
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4.12 Design of antisense miRNA-expressing dumbbells 
As miRNAs are important posttranscriptional regulators of metazoan gene expression, both 
their overexpression and functional inhibition can be of therapeutic value. Most miRNA 
antagonists are chemically synthesised oligodeoxyribonucleotides with antisense orientation 
to the miRNA and/or its precursor (Krutzfeldt, Rajewsky et al. 2005, Wong, Jiang et al. 
2013). Alternatively endogenously transcribed antisense RNA can function as miRNA 
inhibitor. Since both, the miRNA target as well as antisense-based inhibitors are rather short 
sequences, we investigated the possibility to use small dumbbell vectors for antisense 
miRNA expression. As a target we selected hsa-miR-21 which is overexpressed in the 
context of hepatocellular carcinoma (Meng, Henson et al. 2007) and designed four antisense 
miRNA (as-miRNA) structures targeting at the same time the mature miR-21 and part of its 
precursor (pre-miR-21), thus overlapping with one of the dicer cleavage sites. That is, these 
as-miRNAs would be suitable to target the primary miR-21 transcript, pre-miR-21, and/or 
mature miR-21 (Figure 27A). Despite the fact that the available as-miRNA sequence and 
structure spaces were very limited, we identified two highly structured and two less 
structured as-miRNA candidates using in silico tools for RNA secondary structure analysis 
(Patzel and Sczakiel 1998, Patzel 2004). In particular free unpaired ends of antisense RNAs 
were reported to correlate with efficient target binding and activity. Accordingly, our highly 
structured as-miRNAs were selected to fold stable hairpin structures without free ends; the 
less structured antagonists were selected not to fold very stable secondary structures and to 
have free 5’ and 3’ ends (Figure 27B). We designed a luciferase reporter-based miR-21 
sensor plasmid (p21-Sensor) by replacing the firefly luciferase 3’UTR of plasmid pMIR-
Report with a repeat of three miR-21 binding sites as well as dumbbell vectors suitable to 
express the selected ‘unstructured’ (A1 and A3) or structured (A2 and A4) as-miRNAs. CL48 
cells were transfected either with the sensor construct alone or together with the respective 
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as-miR-expressing dumbbell vectors and luciferase activity was monitored 48h post 
transfection (Figure 27D). Interestingly, all four dumbbells/as-miRNAs triggered comparable 
levels of endogenous hsa-miR-21 inhibition as indicated by an about 3-fold increase (p<0.01) 
of luciferase expression.  
 
Figure 27. Functional knockdown of hsa-miR-21 by antisense-miR-21 (anti-miR-21) 
expressing dumbbell vectors in CL48 cells.  
A, Sequences and minimum free energy RNA secondary structures of miR-21-targeting 
antisense RNAs (A1 to A4) as predicted by mfold and RNAfold and positioning relative to 
the miR-21 precursor. B, Design of the miR-21 sensing luciferase reporter plasmid with three 
fully complementary miR-21 binding sites. C, Design of anti-miR-21-A1, -A2, -A3, or -A4-
expressing dumbbell vectors. D, 5x10
4
 CL48 cells seeded in 24-wells were (co-)transfected 
with 100 ng pMIR-21-Sensor alone or together with 100 ng anti-miR-21-expressing 
dumbbell vector DNA and functional miR-21 knockdown was monitored 24h post 
transfection. Error bars indicate standard errors of the mean of two independent experiments.
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Chapter 5 Results 




Besides small non-coding RNAs, protein-coding genes have also been expressed using 
alternative DNA vectors, such as minicircles and dbs. Previous studies have reported that 
both minicircle and db were superior regarding the transgene expression. Db vectors, in 
particular, were used in vivo to express antigens for vaccination purposes (Lopez-Fuertes, 
Perez-Jimenez et al. 2002, Moreno, Lopez-Fuertes et al. 2004). Importantly, recent data 
suggest silencing of foreign DNA vectors is related to the bacterial sequences, including 
antibiotic genes and origins of replication in the plasmid, providing one explanation of the 
observed advantages in alternative DNA vectors (Chen, He et al. 2004). 
Although many genes have been expressed using dbs, most of these expression cassettes used 
the basic design, namely contain only a promoter, the CDS, and a poly (A) signal. Some dbs 
developed by the company Mologen did include a chimeric intron. However, it was not 
mentioned whether the transgene expression was enhanced by this design. We therefore 
studied the effects of molecular elements commonly used in plasmids to improve transgene 
expression, including a chimeric intron and an enhancer. For the design of db vectors, we 
used the chimeric intron derived from the human -globin gene and the SV40 enhancer. The 
intron and enhancer elements were cloned into the pGL3-Control luciferase expression vector 
(Promega) and the expression of the transgene was studied in different cell lines.  
Sustained expression of transgenes in primary cells holds great promise for the treatment of 
many genetic diseases. Currently expression using plasmid vectors is unsatisfactory due to 
the efficient transgene silencing in primary cells. We explored to use db vectors for transgene 
expression in human PBMCs. We produced a GFP expressing db based on the retroviral 
vector MP71-eGFP, which was reported to efficiently transduce T lymphocytes (Engels, Cam 
et al. 2003). We were particularly interested in this vector because it had many elements that 
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were not tested for dbs before, including LTRs for expression induction, the designed MESV 
intron, and the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) 
element, which has been shown to improve mRNA processing and nuclear export as well as 
transgene expression. We used the Nucleofection technology to introduce the parental 
plasmid and db into the target cells. Long-term expression was examined in both Jurkat cells 
and PBMCs and the kinetics of GFP expression were compared.  
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5.2 A spliceable intron and/or the SV40 enhancer improve dumbbell-driven gene 
expression 
Most dumbbell vectors reported in the literature were designed to express functional proteins 
and, hence, much larger in size compared with the small RNA expressing dumbbells 
discussed in the previous chapter. We investigated as to whether the full length SV40 
enhancer would be suitable to enhance protein expression driven by large dumbbell vectors. 
As a second molecular feature to enhance protein expression we implemented a spliceable 
intron. While the implementation of introns into dumbbell vectors was reported earlier 
(Schirmbeck, König-Merediz et al. 2001), SV40 enhancer elements have not been described 
in dumbbells yet. Using the ELAN loop-ligation method we generated a dumbbell vector 
containing a SV40 promoter-driven firefly luciferase gene and the SV40 polyadenylation site 
(db-luc) as well as variations of this parental vector harbouring either the full-length SV40 
enhancer (db-luc-enh), the human -globin gene chimeric intron (db-int-luc), or both (db-int-
luc-enh) (Figure 28A). As controls we constructed four plasmid vectors having identical 
expression cassettes and features but which in addition contained the 2855 bp pGL3-Control 
backbone. The quality of the db production was assessed by agarose gel electrophoresis 




Figure 28. Db vectors for the study of intron and enhancer effects.  
A. Schematic illustration of the four luciferase expression dbs. Design of dumbbell vectors. 
db-luc: parental vector; db-luc-enh: SV40 enhancer dumbbell; db-int-luc: intron dumbbell; 
db-int-luc-enh: intron-enhancer dumbbell. B. 0.8% agarose gel electrophoresis of the four 
luciferase dbs after exonuclease treatment. Only one band with the correct size remained after 
exonuclease treatment, indicating thorough clearance of by-products. 
 
HEK293T and HepG2 cells were transfected with equimass amounts of the plasmid and 
dumbbell vectors and luciferase gene expression was monitored 48h post transfection. In 
HEK293T cells, plasmids and dumbbells triggered a comparable level of gene expression; in 
HepG2 cells dumbbell-triggered expression was 3 to 7-fold (p<0.001) stronger (Figure 
29A,B). While the implementation on an intron enhanced gene expression of all constructs 
unconditionally and in both cell lines, the SV40 enhancer was active in HepG2 cells but not 
in HEK293T cells in which the SV40 enhancer slightly impaired gene expression. In HepG2 
cells, implementation of the SV40 enhancer triggered a remarkable 16-fold (p=0.005) or 27-
fold (p<0.001) enhancement of luciferase expression compared with the respective enhancer-
negative dumbbells db-luc or db-int-luc. Highest levels of luciferase expression were 
triggered by dumbbell db-int-luc in HEK293T cells and by the dumbbell db-int-luc-enh in 
HepG2 cells. In HepG2, db-int-luc-enh-triggered gene expression was 7-fold higher (p<0.001) 
than for the equally featured plasmid p-int-luc-enh and 160-fold higher (p<0.001) compared 
with the basic plasmid p-luc. These numbers are still remarkable when considering the about 
50% smaller dumbbell size and the approximate two fold higher molar dumbbell amounts 




Figure 29. Enhancement of dumbbell vs. plasmid-driven luciferase expression by the -
globin gene chimeric intron and/or the full length SV40 enhancer.  
5x10
4 
HEK293T or HepG2 cells seeded in 24-wells were transfected with 400ng dumbbell 
vectors or equivalent amounts of parental plasmids. Luciferase expression triggered by 
equimass amounts of dumbbell vectors and plasmids was measured 48h post transfection. 
Error bars indicate mean deviations from average of three to five independent experiments.  
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5.3 Enhancement of gene expression triggered by the SV40 enhancer is most likely due 
to transcriptional activation 
Having demonstrated that SV40 enhancer could significantly increase the transgene 
expression in HepG2 cells in the db context, we next explored the mechanism of the 
enhancement. It has been reported that the SV40 enhancer can facilitate active nuclear DNA 
import and/or enhance transcription activation. Because luciferase expression by our vectors 
was driven by SV40 promoter, we speculated that a substantial level of gene expression 
enhancement might occur at the transcriptional level, because the SV40 enhancer efficiently 
supports its homologous promoter. We therefore changed the promoter from SV40 to CMV 
to create another four luciferase expression vectors (Figure 30A). Vector sequences were 
confirmed by sequencing. Next HepG2 cells were transfected with the four new constructs 
driven by CMV promoter. As speculated, the earlier observed advantage triggered by the 
SV40 enhancer was lost when the promoter was changed to CMV (Figure 30B). No 
significant difference in gene expression was detected between luciferase and luciferase-
enhancer constructs anymore. Moreover, expression from the plasmid was reduced more than 
50% when chimeric intron was present, suggesting proper splicing was impaired. Since we 
inserted the intron in the 5’-UTR, replacement of the promoter might have affected the 
activity of the intron because initiation sites are different for different promoters. It should be 
emphasized that inclusion of the intron did not increase the expression levels as expected. 
Absolute expression levels from all four CMV constructs were 110- to 1700-fold higher than 
their SV40 counterparts (p<0.05), indicating the CMV promoter is a much stronger promoter 




Figure 30. The effect of SV40 enhancer is more likely to be at the transcriptional level.  
A. Schematic illustration of CMV-driven luciferase plasmids. Design of CMV plasmid 
vectors. CMV-luc: parental vector; CMV-luc-enh: SV40 enhancer vector; CMV-int-luc: 
intron vector; CMV-int-luc-enh: intron-enhancer vector. B. 5x10
4
 HepG2 cells seeded in 24-
wells were transfected with 400ng CMV-driven luciferase plasmids. Luciferase expression 
was monitored 48h post transfection. C. Comparison between CMV-driven luciferase 
constructs and their SV40-driven counterparts. 5x10
4
 HepG2 cells seeded in 24-wells were 
transfected with 400ng either CMV-driven or SV40-driven luciferase plasmids. Luciferase 
activity was measured 48h post transfection. Error bars represent standard errors of the mean 




5.4 Features from MP71-eGFP retroviral vector 
Currently viral vectors are most frequently used for ex vivo gene transfer. Despite their 
efficient transduction of the target cells, genomic integration-related side effects or immune 
stimulations have been reported (Hacein-Bey-Abina, Von Kalle et al. 2003, Cavazzana-
Calvo, Payen et al. 2010). Non-integrating DNA vectors, on the other hand, are limited by 
their inefficient expression in primary cells. Engels et al. reported an improved retroviral 
vector, MP71, which showed stable, high-level expression in T lymphocytes (Engels, Cam et 
al. 2003). In their study, this new vector yielded up to 75-fold higher transgene expression 
level compared with the standard Mo-MLV vector in various cell lines and in primary T 
lymphocytes. Although this retroviral vector was designed for transduction, we decided to 
use the expression cassette of this vector, which contains many new molecular elements, in 
the db context. These features include an optimized 5’- UTR and the woodchuck hepatitis 
virus posttranscriptional regulatory element (WPRE). The MP71-eGFP vector was provided 
by our collaborator Prof. Antonio Bertoletti and the corresponding db vector was generated 
from this parental plasmid using the ELAN loop-ligation method. We compared GFP 
expression triggered by the db vector with the corresponding plasmid in the human T cell line 
Jurkat and the PBMCs using the nucleofection delivery technology. The structure of the GFP 




Figure 31. Schematic illustration of the GFP expression db and design of nucleofection 
experiment. 
 
Instead of a conventional promoter such as CMV or SV40, expression of this GFP db was 
triggered by the retroviral LTR sequence (Figure 31). The LTRs used in this vector originate 
from murine myeloproliferative sarcoma virus (MPSV), which was shown to trigger 
increased transgene expression in various types of cells, including T cell lines, as well as in 
mouse and in human lymphohematopoietic cells (Baum, Hegewisch-Becker et al. 1995, 
Halene, Wang et al. 1999, Hawley 2001). An optimized 5’ untranslated ‘leader’ sequence 
was also included in the vector. It was shown previously by Hildinger et al. that the leader 
sequence, which removed all aberrant AUGs, together with the inserted the intron derived 
from murine embryonic stem cell virus (MESV), promoted mRNA export and translation 
(Hildinger, Abel et al. 1999, Schambach, Wodrich et al. 2000). Another cis element in the 
vector is the WPRE. Instead of promoting transcription or splicing, this element may improve 
gene expression by modification of polyadenylation, and nuclear RNA export (Donello, Loeb 
et al. 1998, Schambach, Wodrich et al. 2000). 
131 
 
Jurkat cells and human PBMCs from healthy donors were electroporated using equimass and 
equimolar amounts of dbs or the parental plasmid vector by nucleofection. In the original 
publication, the MP71-eGFP vector was used to transfect the packaging cell line in order to 
produce viral particles, therefore the expression efficiency triggered by this vector is 




5.5 Dumbbell vectors triggered enhanced levels of transient and sustained transgene 
expression in Jurkat cells 
Our vectors, db or plasmid, were delivered via nucleofection into Jurkat cells. Both equimass 
and equimolar amounts of dbs (as compared with the plasmid) were used for the 
nucleofection, and expression levels of the GFP were determined by flow cytometry analyses 
until day 107 post delivery. Figure 32 shows the flow cytometry dot plots for Jurkat cells 
transfected with plasmid MP71-eGFP as well as equimass or equimolar amounts of GFP dbs, 
highlighting the data for Days 8, 14, 21, 42, 79, and 107. The bar diagrams show the number 
of GFP positive cells as well as their mean fluorescence and median fluorescence intensities. 
From Day 8 onwards, dbs showed stronger GFP expression as compared with the plasmid. 
Two weeks post delivery, the number of GFP positive cells in the plasmid group decreased 
drastically, as compared with the db groups in which still many GFP positive cells were 
detectable. Moreover, transgene expression levels were also higher in the db groups. It was 
quite impressive that we could detect relatively high levels of GFP expression fifteen weeks 
after the nucleofection experiment. The complete gene expression kinetics were summarized 
in Figure 33. The percentage of GFP positive cells was high within the first ten days and 
persisted on a lower but steady level to the end of the experiment of Day 107. This 
expression profile might indicate a strong transient gene expression triggered by episomal 
vector DNA followed by a weaker persistent expression triggered by integrated vector DNA. 
We speculate that the more sustained expression observed here in db groups might be due to 













Figure 32. Db vectors triggered enhanced levels of transient and sustained transgene 
expression in Jurkat cells. 
Flow cytometry analyses of Jurkat cells nucleofected with GFP expressing plasmid and dbs. 
5x10
6
 cells were nucleofected with 1000ng plasmid, equimass or equimolar (550ng) amounts 
of db vectors in 100 µl Single Nucleocuvette™ (Lonza) using pre-set program EO-115. 
Jurkat cells nucleofected with no DNA served as the mock. Cells were collected and analysed 
by flow cytometry regularly post nucleofection experiment. Data on Day 8, 14, 21, 42, 79, 
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and 107 are highlighted. Percentage as well as the mean and median intensities of GFP 
positive cells, calculated using the single cell analysis software FlowJo (Version 7.6), are 
shown in the bar diagrams. Data are collected from one experiment. 
 
Figure 33. Kinetics of GFP expression in Jurkat cells.  
Mean, median fluorescent intensities (A) and percentage of GFP+ cells (B) data collected 





5.6 Higher long-term expression levels triggered by the dumbbell are mainly due to 
more efficient genomic integration 
In order to determine whether the higher levels of long-term transgene expression observed 
for db groups were due to genomic integration, we isolated the RNA, episomal DNA and 
genomic DNA from Jurkat cells at Day 79 post nucleofection. Copy numbers of GFP RNA or 
DNA were quantified using rtRT-PCR or rtPCR, respectively. As shown in Figure 34A, we 
detected significantly higher levels (p<0.05) of GFP RNA in the db groups using either 
primer for reverse transcription oligo (dT) or random hexamer, suggesting dbs triggered 
stronger long-term expression of GFP. For the quantification of vector copy numbers, we 
used the same set of primers. With regard to episomal vector quantifications, significantly 
higher levels of DNA vector were detected for the equimass (p<0.05) but not equimolar db 
group as compared with the plasmid group (Figure 34B). Genomic integration, on the other 
hand, was 3.5- to 5-fold higher (p<0.001) for both dumbbell groups as compared with the 
plasmid (Figure 34C). In summary our data suggest that the sustained transgene expression 




Figure 34. Genomic integration of GFP plasmid and db vector.  
79 days post nucleofection 1x106 cells from each group were collected and total RNA (A), 
episomal DNA (B) as well as genomic DNA (C) were isolated. Copy numbers of GFP RNA 
and vector DNA were quantified using SybrGreen rtRT-PCR or rtPCR, respectively. The 
same pair of primers were used for all quantifications. Error bars represent the standard errors 
of the mean of one experiment, technical duplicate.  
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5.7 Dumbbell vectors but not plasmids triggered prolonged transient gene expression in 
primary human PBMCs 
Besides human T lymphocyte cell line Jurkat, we investigated the kinetics of db induced GFP 
transgene expression in human primary cells. PBMCs were stimulated with 600 IU/mL 
interleukin-2 (rIL-2) and 50 ng/mL anti-CD3 antibody in AIM-V 2% AB serum for 7 days 
before the nucleofection. 5x106 cells were mixed with the DNA and placed in the certificate 
cuvette (Lonza). The mixture was electroporated using the program EO-115. Samples were 
collected and analyzed by flow cytometry analyses at various time points post 
electroporation. In primary human PBMCs the gene expression kinetics look very different 
compared with Jurkat tissue culture cells (Figure 35). Prolonged expression triggered by the 
db-vector could be monitored up to day 14 post delivery after which the primary cells died 
due to the tissue cell culture conditions. GFP expression of a conventional plasmid vector 
containing the identical GFP expression cassette plus the bacterial sequence backbone was 
silenced to mock levels within two days as detected by mean and median GFP intensities 
during FACS analyses (Figure 35). A fraction of cells expressing very low GFP levels was 
still detectable in the plasmid sample until day 8 (Figure 36). However, the expression levels 
of these cells were too low to be reflected in the mean and median of expression levels. Our 
preliminary data provide strong evidence that the presented dumbbell-DNA vector-based 
system does not suffer from transgene silencing and instead triggers prolonged transgene 
expression in human primary cells representing a promising tool for genetic therapy of 









Figure 35. Db vectors triggered prolonged transient gene expression in primary human 
PBMCs 
Flow cytometry analyses of PBMCs nucleofected with GFP expressing plasmid and dbs. 
5x10
6
 cells were nucleofected with 1000ng plasmid, equimass or equimolar (550ng) amounts 
of db vectors in 100 µl Single Nucleocuvette™ (Lonza) using pre-set program EO-115. Cells 
nucleofected with no DNA served as the mock. Cells were collected and analysed by flow 
cytometry regularly post nucleofection experiment. Data on Day 3, 8, 10, and 14 are 
highlighted. Percentage as well as the mean and median intensities of GFP positive cells, 
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calculated using the single cell analysis software FlowJo (Version 7.6), are shown in the bar 
diagrams. Data are collected from one experiment. 
 
Figure 36. Kinetics of GFP expression in human primary cells.  
Mean, median fluorescent intensities (A) and percentage of GFP+ cells (B) data collected 





Chapter 6 Discussion 
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6.1 Summary of findings 
In this study we have developed a sensitive and specific RT-PCR method that is suitable for 
detecting and quantifying small RNAs. This new method, based on TaqMan chemistry, uses 
only one probe for the detection of multiple targets. A pre-designed stem-loop RT primer is 
used to specifically capture the 3’ end of the target RNA. The universal probe and the 
universal reverse primer are then used together with a specific forward primer for the 
amplification of the cDNA during the real-time PCR step. Compared with the state-of-the-art 
technology, which uses an individual probe for the detection, we demonstrate that this new 
method is of equal sensitivity and specificity. Since the TaqMan probe is the most expensive 
reagent for the quantification, our new protocol greatly reduces the costs and is more suitable 
for medium- to high-throughput applications. By using stem-loop RT primers with different 
overhangs, we found that a 6 nt overhang was optimal. Single-stranded and double-stranded 
RNA templates can be detected with equal sensitivity, indicating the duplex structure of the 
target RNA did not interfere with the stem-loop RT primer binding. We tested the new 
protocol using various templates, including siRNAs, miRNAs, and miRNA mimics. The new 
protocol was as robust as the conventional one. However, we found the overall sensitivity of 
this strategy was lower than previously reported. This seemed to be intrinsic to the design of 
the strategy because we found the low sensitivity was independent of the target sequences. 
Precursors of miRNAs were synthesized by in vitro transcription, and by comparing the 
detection of precursors vs. mature sequences we demonstrated that the new protocol could 
efficiently discriminate between these two species. Similarly, in another experiment in which 
different mature sequences were used, we also showed that discrimination between the target 
and other potential off-target mature small-RNAs was efficient. We have successfully used 
this method for the quantification of small RNAs of both prokaryotic and eukaryotic 
organisms. Finally, by using a series of stem-loop RT primers, we found stem-loop primer-
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based RT protocols in general exhibit limited specificity for RNA 3’ ends. This work has been 
published in the journal, RNA, and in collaboration with another group we have already 
successfully used the method for the validation of miRNA microarray data (Jung, Jiang et al. 
2013, Tan, Choi et al. 2014). 
We investigated novel molecular features for the design of non-coding and coding RNA 
expressing dumbbell-shaped DNA minimal vectors. Expression cassettes particularly for 
small RNAs are about 200 bp in length far below the minimum size of plasmid or even 
minicircle DNA. The use of these two vector systems implies that 80 to 95% of the delivered 
DNA is not the sequence of interest or in other words the resulting vectors are 5 to 20-fold 
larger than necessary. Moreover, the length of extragenic spacers which can be found in most 
plasmids and minicircles but not in dumbbell vectors, was found to correlate with transgene 
silencing in primary cells. Here we describe a strategy to further minimise the size of shRNA 
or miRNA-expressing dumbbells by (i) using a novel minimal promoter-terminator element 
to control (ii) the transcription of a hairpin DNA template. That way we succeeded to shorten 
small RNA-expressing dumbbells by 33% to a size of about 130bp. To our knowledge, these 
are the smallest functional expression vectors ever produced. Such minimised hairpin-
template transcribing dumbbells can be produced with conversion yields of about 90% using 
a novel protocol that amalgamates features of the conventional ELAN and nicking enzyme-
based production methods. 
We have directly compared the activity of minimal H1, full-length H1, and CMV promoters 
for small-RNA expression. Our data demonstrated that minimal H1 promoter was ideal for 
our applications. We studied the kinetics of transfection, transcription, and nuclear import, 
using plasmid, conventional linear db, and hairpin db. By using different transfection 
reagents, we demonstrate that dbs could be introduced into tissue culture cells by lipofection-
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based transfection. Db transfection was at least as efficient as transfection of conventional 
plasmid DNA. We showed dbs induced much higher levels of small-RNA expression, as 
measured by the stem-loop primer-based RT-PCR protocol. Both dbs, a db with a linear 
transcription unit and a db with a novel hairpin transcription unit, showed comparable high 
levels of expression, indicating the circular transcription was at least as efficient as 
conventional linear transcription. We detected up to 57-fold more db vectors in the nucleus, 
suggesting the diffusion of these small vectors into the nucleus was more efficient than that 
of the plasmid counterpart. Observed higher levels of transgene expression were probably 
due to the more efficient nuclear import. Because of the unique configuration of our db 
design, we were able to integrate the inverse 5T termination signal into the mH1 promoter. 
This modification further decreased the overall size and simplified the production procedure. 
By measuring the knockdown efficiency we showed this modification did not compromise 
the potency of the construct. We have also investigated a miR-stem for shRNA-expressing 
dbs and showed inclusion of the stem enhanced the performance of the vector. Besides 
shRNA, we also explored to use dbs to express natural miRNA and antisense miRNA 
inhibitors. We constructed miRNA-sensors and demonstrated that the sensors were 
responsive to both endogenous and ectopic miRNA levels. By using the miRNA sensor 
system we showed that biologically active natural miRNA as well as antisense miRNA 
antagonists could be expressed using db vectors. A schematic illustration of our work on 




Figure 37. Schematic diagram Highlighting the features of small RNA expressing 
vectors investigated in this study. 
 
Finally, we have also explored molecular elements, including intron and enhancer, which 
have been shown to improve transgene expression in plasmids, for db vector gene expression. 
We have made four luciferase constructs and produced dbs from the parental plasmid using 
the ELAN loop-ligation-based method. Transgene expression was measured in different cell 
lines. Our results showed a chimeric intron derived from the human -globin gene 
significantly increased transgene expression in both 293T and HepG2 cells. While we 
observed dramatic increase of transgene expression triggered by the SV40 enhancer in 
HepG2 cells, no effect was detected in 293T cells, suggesting the effect of SV40 enhancer 
was cell-type specific. The mechanism underlying the enhancer effect was partly studied by 
replacing the promoter of the luciferase vectors. Previous constructs were driven by the 
homologous SV40 promoter, which was known to cooperate with the SV40 enhancer to 
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activate transcription. Because the SV40 enhancer was also proposed to increase the nuclear 
import of non-viral vectors, we investigated the mechanism underlying the observed 
enhancement by replacing the SV40 promoter with the heterologous CMV promoter. CMV-
driven constructs lost the SV40 enhancer effect, suggesting the SV40 enhancer increased 
transgene expression through transcriptional activation, and that the homologous SV40 
promoter was required for this activation. A retroviral vector-derived GFP db with novel 
features including LTRs, an intron, and the WPRE, was tested in cell lines and primary 
human PBMCs. We monitored expression triggered by the GFP plasmid and db for more than 
100 days after nucleofection in Jurkat cells. Our data showed dbs induced higher levels and 
more sustained expression. Further analysis indicated the long-term expression was probably 
due to a higher genomic integration rate. Transgene expression from dbs was also detected in 
primary cells after nucleofection, whereas no expression was detected from the 
corresponding plasmid. These data suggest that plasmids, but not dbs, suffer from transgene 
silencing in human primary cells. A schematic illustration of our work on coding RNA 




Figure 38. Schematic diagram highlighting novel features of coding RNA expressing dbs. 
 
In summary, our experiments and published work (Kobelt, Aumann et al. 2014) suggest db-
vectors can be delivered with equal or superior efficiency as compared with plasmid DNA. 
Considering limitations associated with some delivery strategies e.g. with regard to 
maximally deliverable volumes or toxicity triggered by liposomal or other complexing 
compounds, together with the fact that the total mass of deliverable DNA is limited, it can be 
regarded as a strong advantage of the dumbbell vector system that equimass amounts can 
correspond to much higher molar amounts as compared with larger plasmids. Our data 
demonstrate that an advanced molecular design can achieve both, a further minimisation of 
dumbbell vector size and the successful implementation of molecular helper functions to 
significantly improve dumbbell-triggered RNA or gene expression levels in tissue culture 
cells which might facilitate therapeutic applications of this vector system. Dumbbell vectors 
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represent an attractive alternative to other ‘naked’-DNA-based vectors systems but possibly 




6.2 A universal TaqMan-based RT-PCR protocol for small non-coding RNA detection 
RNAs have been long considered as the central players during gene regulation. The single- 
stranded linear molecular identity and the ability to form complex secondary and tertiary 
structures make RNAs crucial for a variety of cellular processes. The discovery of 
endogenous small non-coding RNAs, in particular microRNAs, established a new paradigm 
of gene regulation. More sensitive and specific methods are needed for detecting and 
quantifying these small RNAs because established techniques such as northern blotting and 
conventional RT-PCR often failed to capture these RNAs. Chen et al. introduced one stem-
loop primer-based TaqMan RT-PCR protocol which was shown to be able to specifically 
capture the 3’ ends of the target RNA (Chen, Ridzon et al. 2005). This protocol is suitable for 
small RNA detection and quantification, but since one specific probe is needed for each 
target, it is expensive and not high-throughput compatible. Nevertheless, since its 
introduction to the research community, the method has been extensively used in many 
laboratories, especially for miRNA profiling. Compared with deep sequencing, RT-PCR 
based method is more cost-efficient and faster, therefore it is more suitable for small scale 
profiling or validation applications. 
Originally, the TaqMan probe was designed to bind to the junction of stem-loop RT primer 
and the reverse transcribed cDNA. However, since the probe binds to the RT primer, in terms 
of sensitivity and specificity, it does not matter if the probe is partially complementary, as in 
the case of the original design, or completely complementary to the RT primer region, as 
shown in our universal protocol. Our data confirmed this hypothesis. As the consequence, 
one universal TaqMan probe can be used to detect multiple small RNA targets. With RNA 
templates derived from chemical synthesis, or isolated from prokaryotes or eukaryotes, we 




For stem-loop RT primer-based RT-RCR method, specificity is reflected by the ability of the 
method to discriminate between the target and other non-template sequences, in particular for 
miRNAs, their precursors and other miRNAs. We have shown that both the conventional 
design and our universal design can efficiently discriminate between the correct targets and 
incorrect off-targets, confirming the hypothesis that for this method, it is the stem-loop RT 
primer rather than the TaqMan probe that triggers the specificity. We observed that the 
discrimination between mature miRNAs was more profound than the discrimination between 
miRNAs and their precursors. These results suggest that precursor sequences which lack the 
correct 3’ binding sites efficiently suppress the binding, albeit not as low as the levels 
observed for the non-matching targets. 
Despite we showed that the universal probe design works equally well as the conventional 
design, some previously unknown limitations of this strategy are revealed, as discussed in the 
following. 
The overall sensitivity of the method is significantly lower than originally reported, and this 
is independent of the TaqMan probe design. We found that for both commercial kits and our 
universal method, the sensitivity was about 100-fold lower than reported. This observation 
was also confirmed by other groups with more targets. Here we do not have a plausible 
explanation because the same buffer condition and equipment was used. However, it seems 
that observed lower sensitivity was independent of the target sequences and probably intrinsic 
to the method design itself. 
Another interesting finding from our experiments is that double-stranded RNA templates and 
single-stranded RNA templates can be detected with equal sensitivity. We used MultiScribe 
reverse transcriptase (Applied Biosystems) which is a modified version of MMuLV reverse 
transcriptase. Strand replacement activity for RNA-DNA and DNA-DNA hybrids of MMuLV 
has been reported, and this may be one explanation for the phenomenon we observed 
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(Kelleher and Champoux 1998). It also suggests that with the current technology we cannot 
distinguish miRNAs in the single-stranded or double-stranded stages. Double-stranded 
miRNAs will form after Dicer cleavage and before the RNAs are loaded into the RNA-
induced Silencing Complex (RISC). Previous studies showed that the availability of 
Argonautes proteins for RISC formation is the limiting factor in RNAi (Grimm, Wang et al. 
2010), therefore RT-PCR-based RNA quantifications will not necessarily correlated with the 
RNAi effector quantity. 
We have used the same FAM-MGB TaqMan probe in this study in order to directly compare 
with the commercial kits which use the same chemistry for probe synthesis. However, the 
underlying chemistry for TaqMan-based RT-PCR is always probe hydrolysis causing a 
fluorescent signal. Therefore other types of probes from different vendors should work 
equally well for this method. The minor groove binder (MGB)-stabilized probes are 
proprietary to Applied Biosystems, this technology greatly increases the melting temperature 
of the probe and as a consequence MGB-based probes are always very short. Besides MGB, 
some other alternative quenchers are also available in the market, such as the BHQ 
quenchers. Probes based on these quenchers will be longer than the probe used in this study, 
but we would not expect any problem in using a longer probe for detection. 
In conclusion, we have developed a universal stem-loop RT primer-based RT-PCR protocol 
for the detection of small RNAs. Our data demonstrate that the universal TaqMan probe 
affects neither the sensitivity nor the specificity of the assay, but such a design allows us to 
detect any target with one probe, thus drastically reducing the cost for detection. Some 
previously unknown limitations that are intrinsic to the method itself were discussed. In Table 
9 we list the advantages and disadvantages for different TaqMan RT-PCT protocols. With the 
standard TaqMan RT-PCR strategy, small RNAs such as miRNAs cannot be captured. 
Individual probes are needed for each RNA target; therefore it combines a high sensitivity 
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with high cost. The original stem-loop primer-based RT-PCR strategy can be used to detect 
both small RNAs and longer targets with defined 3’ ends. The same as the conventional 
TaqMan RT-PCR method, individual probes are used for different targets. In summary this 
protocol retains the high cost but the sensitivity is seemingly lower than the conventional one. 
Our universal stem-loop RT primer-based protocol exhibits the same sensitivity and 
specificity as the original design, but the cost will be significantly reduced when multiple 
targets are to be detected. This new technology would be the most advantageous for high-
throughput applications and represents a cost-efficient method for small RNA detection. 






Sensitivity Very high, less than 10 
molecules per sample 
can be detected 
High, less than 10a/100~1000b molecules per 
sample can be detected 
Specificity Very high, TaqMan 
probe triggers target 
specificity 
High, stem-loop primer triggers target specificity 
Cost High, individual probe 
needed for each target 
RNA 
High, individual probe 
needed for each target 
RNA 
Lower, universal probe 
can be used to detect 
multiple targets 
Applications Detection of RNA except 
small RNA 
Detection of small or 
longer RNA with 
defined 3’ end 
Predesigned and 
custom assays 
Detection of small or 
longer RNA with 
defined 3’ end 
Cost-effective detection 
of multiple targets 
High-throughput 




Table 11. Comparison of real-time RT-PCR protocols.   




6.3 Dumbbell vectors for small non-coding RNA expression 
In this study we have described novel designs for small RNA-expressing db vectors. 
Expression cassettes for small RNAs are less than 200 bp in length, far below the size of 
conventional plasmid and minicircle DNA. Size minimization of small RNA expressing dbs 
was achieved by transcription of a hairpin DNA template and further integration of promoter 
and terminator sequences (iPTR). Such a design allows us to decrease the size of db to 130 
bp. We proposed an efficient new method to synthesize these new vectors. This method 
involved a two-part ligation between the synthesized or PCR-amplified promoter and a 
hairpin DNA template. After optimization we were able to achieve a db vector conversion 
rate of above 90%. It is reasonable to assume that a smaller vector size might be 
advantageous in terms of cellular delivery (depending on the delivery method) and must be 
beneficial with respect to nuclear diffusion. On the other hand and provided the expression 
cassette remains the same, one would expect a comparable transcriptional activity of all large 
or small vector molecules which successfully have reached the cellular nucleus. 
Our study of the early kinetics of dumbbell vs. plasmid-based cellular delivery (equimolar 
amounts) revealed a clear advantage for the larger dumbbell harbouring the linear shRNA 
expression cassette as compared with the plasmid or the minimised dumbbell. That is 
difficult to understand and could be explained by different efficiencies of liposome formation 
for the different vector molecules. On the other hand when using SybrGreen instead of a 
TaqMan-probe for vector quantification, the difference between the conventional and the 
minimised dumbbell strongly diminished, indicating that the observed difference in terms of 
cellular delivery was rather an artefact associated with the TaqMan-probe-based PCR 
detection and the fact that it might be difficult for the TaqMan probe and two primers to 
efficiently bind to a small circular DNA molecule of about 268 nt in length. Both the linear 
and the hairpin dumbbells were equally abundant in the nuclear fraction pointing towards an 
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accelerated rate of diffusion from the cytoplasm into the nucleus in case of the minimised 
dumbbell. Interestingly, the minimised dumbbell exhibited a significantly enhanced 
transcriptional activity 10min after transfection started. Only in the case of the minimised 
dumbbell, transcription has to go around the DNA hairpin structure which one would not 
consider advantageous. Thus, the enhanced transcriptional activity can most likely be 
assigned to accelerated nuclear diffusion assuming nuclear diffusion of the minimised 
dumbbell reaches its steady state in less than 10min and that the difference between the 
minimised and the linear dumbbell was not captured anymore by the investigated 10min time 
point.  
Our analyses indicate an inverse correlation between the size of a ‘naked’ DNA-based vector 
and the kinetics of gene expression. This hypothesis was further supported by the observation 
that a miR-125b expressing hairpin template-transcribing minimised dumbbell triggered 
stronger knockdown of a miR-125b sensor luciferase reporter compared with a dumbbell 
harbouring a linear miR-125b expression cassette or a plasmid vector. It is not clear at this 
point whether the slightly improved luciferase knockdown triggered in HepG2 cells by vector 
db-iPTR-hp-s/as as compared with vector db-iPR-hp-s/as can be assigned to the 5bp shorter 
size or the different RNA ends; transcription of the inverted transcriptional terminator adds 
five As to the 5’ end of the db-iPR-hp-s/as- but not to the db-iPTR-hp-s/as-derived transcript 
leading to a 5’ overhang or a more favourable 3’ overhang, respectively. Notably, the 
advantage of the db-vectors as compared with the plasmids in terms of delivery and gene 
expression was found to be highly evident when delivering equimolar amounts of vector 
DNA. It is expected that these advantages become even more pronounced, the more the 
higher the ratio between the mass of the plasmid and the mass of the dumbbell, when 
equimass amounts of vector DNA will be applied. 
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Our observation that a 1000-fold increase in nuclear delivery of all vectors from 10min to 
24h post transfection only triggers an about 10-fold increase in the detectable RNA levels 
during the same period of time could be due to (i) transcriptional inactivation of the vector 
DNA, (ii) enhanced degradation of the transcribed RNA, (iii) incomplete processing of the 
shRNA precursors which are expected be detected with lower sensitivity compared with the 
processed antisense shRNA due to their self-complementarity and formation of stable 
secondary structures, or (iv) toxicity and cell death in the consequence of an oversaturation of 
the cellular silencing machinery (Grimm, Streetz et al. 2006). Though cell death assays were 
not preformed there was no evidence that any of the used vectors triggered cell death. In 
addition, pathway oversaturation and toxicity would be dose-dependent and should be much 
more pronounced in case of the db-vectors which expressed the shRNA at much higher levels. 
However, the discrepancy between the kinetics of nuclear delivery and shRNA abundance 
was independent of the vectors and the corresponding expression levels.   
Besides the attempts to further minimise db-vector size we identified molecular features that 
improve the biological activity (gene expression of small RNA-triggered inhibition of gene 
expression) of dumbbells though they enlarge the overall vector size. One of those features is 
the extension of the shRNA stem with the stem of a natural miRNA. MiRNA stems were 
frequently used to support plasmid-based shRNA expression but have not been reported in 
the context of dumbbells yet. We demonstrated that the implementation of the miR-30 stem 
into a shRNA-expressing minimised dumbbell significantly enhanced shRNA-triggered 
target gene knockdown indicating that improved RNA processing compensates for the 
disadvantages resulting from a 17 bp (34 nt or 12.6%) larger vector size. To transcribe the 
partially mismatched miR-30 stem structure, appropriate mismatches had to be implemented 
into the expression cassette of the dumbbell which obviously did not negatively interfere with 
dumbbell generation and activity. Likewise, the enhanced knock-down activity triggered by 
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db-iPTR-hp-as/s as compared with db-iPTR-hp-s/as is assumed to result from improved 
guide RNA processing and/or RISC loading.  
SV40 enhancer-derived sequences represent another dumbbell enlarging but activity 
improving molecular feature. The minimal or full-length version increased the minimised 
miR-125b expressing dumbbell by 47% or 146% but enhanced target gene knockdown 2.3 or 
4.5-fold. Basically, transcriptional activation as well as active nuclear DNA import and 
retention can account for the enhancement of gene expression triggered by these sequence 
elements (Lam and Dean 2010), though it is unlikely that the SV40 enhancer promotes 
transcriptional activation of the heterologous mH1 polymerase III promoter in this 
experimental setting. The postulated mechanism underlying an active nuclear DNA import is 
that transcription factors harbouring peptide nuclear localisation signals bind to these DNA 
sequences and co-import the bound DNA piggy-back into the nucleus by means of the 
protein nuclear import machinery (Miller and Dean 2009). 
Antisense RNA-mediated inhibition of gene expression is a kinetically controlled process 
(Patzel and Sczakiel 2000), i.e. fast target binding correlates with activity, and longer 
antisense RNAs are faster target binders compared with short antisense RNAs on a statistical 
basis (Patzel and Sczakiel 1999). However, it was also shown that relatively short antisense 
RNAs of about 100nt in length can be very strong inhibitors provided they form flexible 
RNA secondary structures with long free ends (Patzel and Sczakiel 1998, Lehmann, Patzel et 
al. 2000). Thus it was at first view surprising that as-miRNA structures with closed ends were 
as potent inhibitors of miR-21 function as structures with free ends. However, it was also 
reported that unstructured antisense RNA is much more prone to ribonucleolytic degradation 
(Patzel and Sczakiel 1998, Lehmann, Patzel et al. 2000). For the group of very short as-
miRNAs investigated here we hypothesise that (i) the more unstructured RNAs might be 
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faster target binders but less stable whereas (ii) the more structured RNAs might be slower 
binding though more stable and that (iii) target binding is just balanced against endogenous 
RNA stability.  
Although db vectors have already been used to express many genes for different applications, 
such as vaccination and cancer therapy, they have not been explored for small RNA 
expression. To our knowledge, the only study that used db vector for small RNA expression 
was reported by the group of Taki (Taki, Kato et al. 2004).  In this study they used linear 
template to express a shRNA against GFP using U6 promoter. Knockdown of the GFP target 
gene was only monitored using fluorescence microscopy and they did not compare the 
parental plasmid vector with the db. In this study we have designed hairpin db expression 
vectors and for the first time shown the kinetics of cellular delivery, nuclear delivery, and 
transcription of this novel vector. A hairpin-template DNA has never been reported for vector 
design, and in this study we demonstrated that transcription could go around the loop 
structure and generate the correct transcript as designed. Our knockdown experiments 
indicate that the hairpin-template DNA was transcribed as efficient or better than the 
conventional linear template. 
Elevated transgene expression after equimolar gene transfer has been reported for 
minimalistic vectors in several studies (Schakowski, Gorschluter et al. 2001, Schakowski, 
Gorschluter et al. 2007, Kobelt, Schleef et al. 2013), but the underlying mechanism is still 
poorly understood. One explanation is, because db vectors are smaller, the vector uptake is 
increased. In this study we found the transfection efficiencies for db and plasmid were similar, 
but the nuclear uptake was much more efficient for the dbs, probably due to the smaller 
vector size which facilitates passive diffusion into the nucleus. It should be pointed out that 
the dbs studied here are for small RNA expression. These dbs are more than twenty-fold 
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smaller than their plasmid counterparts. For protein-coding gene expression dbs, on the other 
hand, the size difference between the db and the parental plasmid is not that much. 
Accordingly, one can assume that nuclear uptake efficiency would not be as high as seen for 
the small-RNA dbs, if nuclear uptake was solely affected by the vector size. 
For the quantification of plasmid and db vector copy numbers by qPCR, we have used 
standard curves generated by each vector, respectively. The amplification of db vectors by 
PCR was less efficient, possibly due to the bigger tension and faster reassociation during the 
annealing step. A similar phenomenon has also been observed by another group (Kobelt, 
Aumann et al. 2014). Our results indicated that for equal amounts of molecules, the Ct value 
measured for the dbs were generally about 3 cycles higher than those for the plasmids. The 
qPCR data, however, can be misinterpreted if either the db or the plasmid is partially 
degraded during the gene transfer process. It would be more convincing if results from qPCR 
are supported by data obtained from other technologies, such as fluorescent microscopy, 
which is also commonly used to determine vector abundance in vivo. 
A study by Grimm et al. showed that sustained overexpression of shRNA resulted in 
competition of the shRNA with endogenous miRNAs and saturation of the karyopherin 
exportin-5-dependent nuclear export pathway (Grimm, Streetz et al. 2006). This finally led to 
fatality in mice. Similar toxicity was observed by Beverly Davidson’s group in a mouse 
model for Huntingdon’s Disease when shRNAs were overexpressed. Toxicity was attenuated 
when shRNA sequences were placed into miRNA expression systems (McBride, Boudreau et 
al. 2008). In this study we have tested human miR-30 stem, which is the most commonly 
used miRNA stem for shRNA modification (Zeng, Wagner et al. 2002), and our data suggest 
inclusion of miRNA stem improves the potency of the shRNA construct. The positioning of 
the guide strand within a shRNA precursor can affect the silencing activities. Ge et al. 
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reported that for shRNAs with 19-bp stems, the potency was greater when guide strand was 
positioned 5’ to the loop (Ge, Ilves et al. 2010). In their study, chemically synthesized 
shRNAs were used for transfection. Here we have made db-iPTR-hp-s/as and db-iPTR-hp-
as/s to investigate the same question. Db-iPTR-hp-s/as has the sense (passenger)-loop-
antisense (guide) orientation, whereas db-iPTR-hp-as/s positions the guide strand 5’ to the 
loop. In line with the study by Ge and coworkers, db-iPTR-hp-as/s showed greater potency in 
HepG2 cells. However, no significant difference was observed when the same experiment 
was done in HEK293T cells. These data suggest that potency and strand selection of the 
shRNA are cell-type dependent, most likely due to varying abundancies of RNA processing 
proteins. 
 In summary, we reported novel designs of small RNA expression db vectors allowing us to 
generate the smallest expression vector ever reported. We also proposed a novel method to 
synthesize these new vectors and demonstrated that dbs could be efficiently produced by our 
method. Artificial shRNA, natural miRNA, and miRNA antagonists can be expressed by 
these new minimal vectors. The expected transcripts were detected, indicating the novel 
hairpin-template transcription design generated the correct RNA molecules. As compared 
with plasmids, dbs induced significantly stronger small RNA expression, which might be due 
to more efficient nuclear import of these small vectors. Molecular features, such as a miR-
stem, a promoter-terminator integration, were shown here to either improve the vectors, or 




6.4 Dumbbell vectors for coding RNA expression 
Besides small non-coding RNAs, we also explored to use db vectors for protein-coding RNA 
expression. Though most studies published so far used dbs for the same purpose, none of the 
studies focused on molecular elements that might improve the performance of this novel 
vector. We could show that an intron and the SV40 enhancer were able to significantly 
improve transgene expression in the db context. While gene expression was unconditionally 
increased by the chimeric intron derived from the human -globin gene, the effect of the 
SV40 enhancer seemed to be cell-type specific. While we observed dramatic improvement by 
this enhancer in HepG2 cells, no effect was observed in HEK293T cells. Since the luciferase 
expression constructs harboured the SV40 promoter together with the SV40 enhancer, we 
speculated that the improvement we observed for the larger dbs might be due to 
transcriptional activation triggered by the cooperation between these two elements. This 
hypothesis was supported by an experiment in which we replaced homologous the SV40 
promoter by the heterologous CMV promoter. In this context previously observed enhancer 
effect was lost, suggesting that the SV40 promoter was indispensable for the enhancer effect. 
Our promoter comparison further revealed that the CMV promoter induced much stronger 
transgene expression. Therefore the CMV promoter seems to be a better choice for ectopic 
transgene expression. 
We have also tested a GFP expressing db derived from a retroviral vector with some 
interesting molecular features, including LTRs, an intron and the WPRE. Our data showed 
the db induced higher levels of transient and sustained expression in Jurkat cells than the 
plasmid vector. Expression levels from db and the parental plasmid were monitored for more 
than 100 days. By analyzing the DNA and RNA from the cells we concluded that the 
advantage observed for the db in terms of long-term expression was probably due to a more 
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efficient genomic integration. We then studied the vectors in primary cells using 
nucleofection as the delivery method. In this experiment only dbs showed transgene 
expression while the plasmid group remained completely negative. However, in this 
experiment we were only able to monitor the expression for up to 14 days, and the survival 
time for primary cells varied from batch to batch. In summary, our data suggest plasmid 
DNA, but not db vectors, suffer from transgene silencing in primary cells. 
The SV40 enhancer represents one of the best characterized transcriptional regulators. It is 
composed of a cluster of cell-type-specific regulatory elements, which cooperate with each 
other to activate transcription (Herr 1993). Based on sequence analyses, several proteins, 
including TEF-1, TEF-2, NF-B, and Octa, were shown to bind to this enhancer region. 
Studies using synthetic proto-enhancers also showed that each subdivided region displayed a 
unique pattern of cell-specific activity (Ondek, Shepard et al. 1987, Schirm, Jiricny et al. 
1987). In agreement with previous studies, we observed cell-type specific enhancer activity 
in db vectors as well. Implementation of the full length SV40 enhancer in much larger SV40 
promoter-driven luciferase expressing dumbbells and plasmids improved gene expression by 
more than an order of magnitude in HepG2 but not in HEK293T cells. It is reasonable to 
assume that cell line-specific transcription factors trigger nuclear DNA import and/or 
transcriptional activation of these constructs in the context of the homologous SV40 
promoter. The observed slight impairment of db-driven luciferase expression in HEK293T 
cells triggered by the SV40 enhancer could be assigned to the larger size of the enhancer-
positive vectors. 
The chimeric intron used in our study was composed of the 5’-donor site from the first intron 
of the human -globin gene and the branch and 3’-acceptor site from the intron that is 
between the leader and the body of an immunoglobulin gene heavy chain variable region 
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(Bothwell, Paskind et al. 1981, Senapathy, Shapiro et al. 1990). The total length of the intron 
is only 132 nt. Studies have demonstrated that an intron in the pre-mRNA frequently 
improves transgene expression (Buchman and Berg 1988). Although introns have been 
previously used in db vectors in some studies (Schirmbeck, König-Merediz et al. 2001), there 
has been no direct comparison between dbs with and without an intron. In eukaryotic cells, 
splicing facilitates nuclear mRNA export and subsequent gene expression (Valencia, Dias et 
al. 2008). Accordingly, the implementation of a spliceable intron enhanced gene expression 
of all dumbbells and plasmid vectors in both investigated cell lines. In addition, gene 
expression enhancement in HepG2 cells indicates that the SV40 enhancer and the intron 
enhance gene expression synergistically. Whereas the enhancer or the intron alone improved 
gene expression of the dumbbell 2-fold or 16-fold, both together triggered an about 56-fold 
enhancement of gene expression. Splicing mainly occurs co-transcriptionally and our 
observation is in line with reports suggesting a link between the polymerase II transcription 
machinery and the spliceosome (Corden and Patturajan 1997).   
The LTR regions of retroviruses show transcriptional activity in a variety types of cells 
(Gorman, Merlino et al. 1982). In this study we chose the LTR regions from the 
myeloproliferative sarcoma virus (MPSV) because these LTRs led to increased transgene 
expression in myeloid stem cells, T cell lines as well as mouse and human 
lymphohematopoietic cells (Engels, Cam et al. 2003). We showed that db-triggered gene 
expression driven by the MPSV LTR sequences induced strong overexpression of GFP in the 
T cell line Jurkat. Notably, when introduced into the target cells by nucleofection, we 
observed more frequent genomic integration events for the db than for the plasmid vector, 
probably as a direct consequence of improved nuclear delivery. 
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In primary cells, we only observed db-driven transgene expression, whereas plasmid 
nucleofection showed no expression after day 3 post nucleofection. Previous studies have 
shown that plasmid DNA is efficiently silenced in vivo even though the vector is not 
degraded (Chen, He et al. 2004, Chen, Riu et al. 2008). Bacterial sequences, which are 
essential for plasmid production, were shown to be responsible for vector silencing. A recent 
study by Kay and coworkers demonstrated that the extragenic spacer length between the 5' 
and 3' ends of the transgene expression cassette was responsible for transgene silencing of 
plasmid-based vectors (Lu, Zhang et al. 2012). The minimized design renders db vectors free 
of any non-essential sequences. In agreement with previous reports, our preliminary data 
indicate that db vectors are not silenced in primary cells. However, further optimization 
might be necessary to achieve higher transgene expression for therapeutic purposes. 
In summary, we have used dbs to express luciferase and GFP reporter genes in both a tissue 
culture cell line as well as in primary cells. Some molecular features, such as an intron and an 
enhancer, were demonstrated to increase db-driven transgene expression. A retroviral vector-
derived GFP Db induced more sustained expression in Jurkat cells than the parental plasmid. 
In primary cells, only db vector-triggered expression was observed, suggesting db vectors do 
not suffer from transgene silencing in primary cells.  
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6.5 Limitations of the study 
One main limitation of the study is for small-RNA expression dbs we measured the total 
levels of shRNA precursor and processed guide RNA without being able to distinguish 
between those. It is well established that levels of shRNA precursors do not always correlate 
with those of mature sequences. In order to achieve specific knockdown of the target gene, 
barriers including nuclear export or processing by RNase III enzymes still need to be 
overcome. It is therefore of great importance to determine the optimal dosage if shRNA 
constructs are to be used for in vivo applications. Processing of shRNA precursor affects the 
efficacy and potential off-targeting. Gu et al. have demonstrated that cleavage of shRNAs by 
Dicer is heterogeneous, and this is responsible for potential off-target effects (Gu, Jin et al. 
2012). In order to detect and understand the heterogeneous nature of the processed siRNAs, 
one could consider deep sequencing of the small RNAs. 
Human peripheral blood is a complex mixture of cells, with lymphocytes and monocytes as 
the major populations. PBMCs are primary cells and they cannot be cultured for more than 
one passage under normal conditions. In our study we have stimulated lymphocytes with IL-2 
and anti-CD3 OKT-3 antibody. Cells were cultured in media with stimulators for one week 
before the experiment was done. Monocytes are considered in the terminal stage and do not 
proliferate. Even though lymphocytes were stimulated and expanded, the cells could only 
survive for a limited period of time. Thus, the life span of PBMCs is too short to study db-
triggered long-term gene expression. In order to compare the vector silencing profiles of dbs 
and plasmids, in vivo studies may be more suitable. In vivo studies with dbs are necessary to 




6.6 Future work 
Because of their special molecular configuration, db vectors are much easier to be linked with 
other biologically active molecule, such as peptides, antibodies, or fluorophores. It would be 
of interest to conjugate dbs with these molecules to improve their performance or to achieve 
specific targeting of certain tissues or cells. Conjugation of dbs with nuclear localizing 
peptides has already been investigated, but mainly for vaccination purposes (Zheng, Juhls et 
al. 2006, Choi, Jeon et al. 2007). It has been reported that covalent linkage of NLS peptides 
to antigen-coding dbs enhanced immune responses in mouse models. A direct comparison of 
nuclear import between dbs with and without NLS conjugation would provide more 
information for vector development. Some other DNA sequences with similar functions as 
the SV40 enhancer can be further investigated. For example, the oriP sequence from the 
Epstein-Barr virus (EBV), which led to up to 100-fold increase of transgene expression in 
EBNA1 positive cells (Langle-Rouault, Patzel et al. 1998), could be another promising 
candidate in particular to explore dbs for targeting of EBNA1-positive cancer cells. 
Studies by Mark Kay’s group have shown that silencing of foreign DNA is linked to 
chromatin modifications and bacterial sequences such as antibiotic genes and origins of 
replication (Chen, He et al. 2003, Gracey Maniar, Maniar et al. 2013). Minicircles devoid of 
these sequences result in persistent high-level transgene expression in vivo. Similar to 
minicircles, db vectors only contain elements essential for transgene expression, and studies 
also showed dbs trigger improved transgene expression in vitro and in vivo. It would be 
interesting to study the chromatin status for dbs in vivo and compare that profile with 
minicircles. It would be interesting to perform epigenetic studies and to monitor the impact 
on transgene expression. Recent research in vivo suggests that episomal vectors undergo 
chromatinization and that histone H3 lysine 4 trimethylation (H3K27) rather than DNA 
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methylation is associated with transcriptional plasmid silencing (Chen, Riu et al. 2008, 
Gracey Maniar, Maniar et al. 2013). Transgene silencing in primary cells also occurs ex vivo. 
One could investigate H3K27 methylation for our db-vectors, compare it with the analogue 
plasmids, and try to correlate it with the methylation status of the cells, the duration of gene 
expression and vector design. This could be done by chromatin immunoprecipitation (ChIP) 
analyses using an anti-trimethyl H3K27 antibody and subsequent real-time PCR 
quantification of the immuno-precipitated DNA (dumbbell, plasmid, and selected genomic 
targets) as described in detail elsewhere (Riu, Chen et al. 2007).  
There have been limited studies of the performance of dbs in vivo. Schakowski et al. have 
studied the biodistribution of dbs in one study (Schakowski, Gorschluter et al. 2007). 
However, mice were sacrificed 8 hrs post vector infusion and no information of long-term 
performance of the vector was reported. Investigation of long-term performance of dbs in 
vivo would be very important for future development and optimization of the vector. 
Another important future aspect will be to monitor vector toxicity and safety profiles. Using 
the imaging flow cytometry system ImageStream Mark II (Amnis) it will be possible to 
monitor vector integration as a function of vector design using the fluorescence in situ 
hybridization in suspension (FISHS) technology, and vector toxicity (apoptosis and necrosis) 
using the annexin V cell death assay which is already established in our laboratory. The rates 
of potential genomic vector integration could be precisely monitored by deep sequencing. 
Conventional techniques such as rt-PCR-based quantification of vector delivery (cytoplasm 
vs nuclei), vector integration rates, and alternative cell viability and cell death assays 
including alamar blue and tunnel assays can be performed to validate such derived data.  
Another long-term plan is to combine coding and non-coding RNA expression dbs, as well as 
other technologies for therapeutic applications. Our lab focuses on designing and 
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optimization of nucleic acids and currently we are exploring to use db vectors to deliver 
trans-splicing nucleic acids to target Hepatocellular Carcinoma (HCC) as well as CRISPR-
Cas9 system for genomic repair of the Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency. We have constructed a minimal-sized dumbbell vector expressing both the RNA 
guide sequences and the Cas9 protein to target the G6PD-Mahidol mutation, a common 
deficient variant encountered in Southeast Asia. We expressed both coding and non-coding 
RNA using this dumbbell vector, thus combined the two technologies we developed. Our 
preliminary data showed with dumbbell vector expression system we could successfully 
introduce the desired genome editing in tissue culture cells, and the efficiency of the editing 
was higher than that of traditional plasmid. This was probably due to the more sustained 
expression from coding dumbbells as shown in this study. Recently Maruyama et al. reported 
that efficiency of precise genome editing with CRISPR-Cas9 could be increased by inhibition 
of the nonhomologous end joining (Maruyama, Dougan et al. 2015), an undesired alternative 
DNA repair pathway that competes with homology-directed repair (HDR). In that study, they 
used small molecule inhibitor to target DNA ligase IV, an enzyme crucial for nonhomologous 
end joining. They showed by the inhibition of DNA ligase IV the genome editing efficiency 
in mammalian cell lines was increased up to 19-fold. Our work on small non-coding RNA 
expression dumbbells already showed that these novel small vectors were superior compared 
with the plasmids. By using the small RNA expression db against DNA ligase IV gene 
together with the CRISPR-Cas9 expression db we can further increase the precise editing by 
CRISPR technology, and this holds great promise to treat a number of diseases. Currently we 
are testing this in human primary cells for reversal of the G6PD-Mahidol point mutation. If 
this strategy is successful we can further apply it to other diseases. The combination of 
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Appendix I: List of oligonucleotides and probes. 




BamH1-hH1-R TGCAGGATCCCTGTGCTCTCATACAGAACT   
BamH1-hH1-
pA-R 



























GCCCTTTGGTCCCCTTCAAC   
miR-146a-Stem-



















GTGCAGGGTCCGAGGT   
Universal 
Taqman Probe 



























































































Bpu-Fw TTAGGAGTTTTCTCCTAAGC 5'PO4 







BamH-Loop GATCTGACCAGTTTTCTGGTCA 5'PO4 
Spe-Loop CTAGAGACCAGTTTTCTGGTCT 5'PO4 
Nde-Loop TAATGTCCAGTTTTCTGGACAT 5'PO4 




Sac-fSV40-Fw ATGCGAGCTCCGATGGAGCGGAGAATGG  

















Not-Loop GGCCGATACCAGTTTTCTGGTATC 5'PO4 
qLUC-Fw CGCTGGGCGTTAATCAAAGA  
qLUC-Rv GTGTTCGTCTTCGTCCCAGT  
MIDGE-Fw GGCCGCTCTAGAACTAGTGGA  







Nsi-Loop GTCCATGTTTTCATGGACTGCA 5'PO4 












D-Fw GAGCTGTTTCTGAGGAGCCTTC  
E-Fw AGGCTCCTCAGAAACAGCTCTTC  
Dmod GATCTAAAAAGAGCTGTTTCTGAGGAGCCTCT
CTTGAAGGCTCCTCAGAAACAGCTCTTTTTA 
5'PO4 
Emod GATCTAAAAAAGGCTCCTCAGAAACAGCTCTC
TCTTGAAGAGCTGTTTCTGAGGAGCCTTTTTTA 
5'PO4 
Dmod-stem-loop GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC
ACTGGATACGACAAGAGC 
 
Emod-stem-loop GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC
ACTGGATACGACAAAGGC 
 
BamH-h1-Rv-
mod 
ATGCAGGATCCCTCTCATACAGAACTTATAAGA
TTCCCAAATC 
 
 
 
